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Resistance of Plasmodium falciparum (P. falciparum) to well-established 
drugs throughout the world has necessitated urgent alternative treatment 
for malaria. Iron chelation therapy was considered as a possible approach 
since iron has been found crucial in the metabolic pathways of 
P. falciparum. 
A series of novel iron chelators were designed and synthesized based on 
thiosemicarbazone and/or ferrocenyl moieties. The novel compounds were 
characterized by NMR, infrared (IR) and mass spectroscopy as well as 
microanalysis and subjected to biological evaluation. 
All the N-substituted ferrocenic thiosemicarbazones were evaluated against 
a chloroquine resistant W2 strain of the malaria parasite P. falciparum and 
enzymes (falcipains 2 & 3) derived from the same parasite. The 
intermediate thiosemicarbazone thioesters were also tested against different 
malaria parasite including chloroquine resistant (K1) and chloroquine 
sensitive (307) strains as well as against the causative agent of African 
trypanosomiasis, Trypanosoma brucei (T. brucei). 
Of the intermediate thiosemicarbazone thioesters, compound 44y a bipyridyl 
compound was the most active against both K1 and 307 strains with 
ED50 values of 0.18 /lg/ml (0.625 /lM) and 0.021 /lg/ml (0.072 /lM), 
respectively. However, this compound 44y also showed similar toxicity to 
mammalian cells. A number of thiosemicarbazone thioesters displaying 
preferential potency against a chloroquine resistant (K1) strain were noted. 
For example, compounds 44a-h, 44k-m, 445, 44u-v were found to be more 











Against T. brucei, compound 44x and 44y were the most active with an 
ED50 of 0.12 J.lg/ml (0.52 J.lM) and 0.15 J.lg/ml (0.53 J.lM), respectively . 
Within the synthesized N-substituted ferrocenic thiosemicarbazones, bipyridyl 
compound 420 was found to be the most active against W2 strain with 
an IG50 of 0.11 J.lM compared to the rest but moderately active against the 
enzymes, FP-2 and FP-3, with IG50 values of 36.20 J.lM and 31.02 J.lM, 
respectively. Being a metal chelator, this N-substituted thiosemicarbazone 
could mechanistically also act as a metal-interactive cysteine protease 
inhibitor. 
The electrochemical behaviour of these compounds was measured for 
correlation purposes between biological activities and electrochemical 
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Malaria is 0118 01 the most significant infectious diseases in the world. It is 
endemic throughout the entire tropical region of the earth except for high 
mountain areas, deserts and a few islands,11 ] 
It has been reported that mortality from malaria is over one million 
persons worldwide eadl year and the most affected are chi ldren under 
five years old, The disease presents a publiC health problem for 2.4 bil lKln 
people which represents over 40% of world population in 90 countries, [2] 
1.1 Disease 
Malaria is a protozoal disease caused by a parasite of the genus 
Plasmodium spread to humans via bites by female mosquitoes, Anopheles 
(Fig11). 
Four species of Plasmodium are responsible for human malaria namely P 
'{wax, p , ma/ariae, P ovale and p , falciparum Of these foor strains, P. 
fa/clparum is the most deadly. This parasite is commonly found in tropical 
Africa. South America and South East Asia including the Indian Sub-
continent, and claims more than 95 % of the malaria related deaths in 











Each year the number of patients who are suffenng from malaria is 
around 300 million which is five times as many as the combined cases of 
tuberculosis, AIDS, measles and Ieprosy[5-6] 
The increase In malaria cases is due to many reasons including human 
migration, as well as land utilizallon especially plantation agriculture. This 
leads to contamination of the previously safe areas such as the highland 
areas of East Afnca [91 The map below shows that over 90% of the 
African continent is In danger from the disease 
o Chloroqui". R •• i,lonl Malaria 
M"~dr"g-R •• ;"lont Malar;" 
Figure 1.2. Malaria distribution on the Worldl''1 
Other reasons for the disease pro~feration include the multidrug resislance 
(MDR) that the parasite has developed towards the we~-established drugs 
and insecticides_ Currentty, MDR is known to be the biggest drawback 
towards development of an effective chemotherapeutic agent Knowledge of 











methods of prevention. treatment and research endeavours of this fatal 
desease 
1.1.1. Life cycle of the malaria parasite 
The malaria parasite's life cycle shown in Fig 1.3. engages two hosts, 
human and mosquito During a blood meal, the malaria-infected female 
Anopheles mosquito injects sporozoites into the human host (1). 
Sporozoites infect liver cel ls (2) and mature into sdlizonts (3), which 
rupture and liberate merozOiles (4) After this in ibal replicatlOll in the liller 
(exo-.erylhrocytlc schizogony A), merolOites infect red blood cells (5) and 
the parasites go through asexual multiplication in the erythrocytes 
(erythrocyte schizogony B) The ring 
schizonts, whiCh break releas ing 
differentiate into the sexual erythrocytic 
o --
stage trophOloites mature into 
merozoites (6). Various parasites 
stage (gametocytes) (7) 
". ;-~, -'" , ,~ , • .'j.-'" 
--."6-['" e 
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Malaria symptoms such as chills, fevers, and nausea start at the blood 
stage. Moreover, it is at this stage that the young parasites, merozoites, 
attack erythrocytes and progressively break down human haemoglobin into 
amino acids and destroy the erythrocytes for its function.[12] 
The gametocytes, male ( microgametocytes) and female (macrogametocytes), 
are ingested by an Anopheles mosqUito during a blood meal (8). The 
parasites reproduce in the mosquito (sporogony cycle) (e), while in the 
stomach the microgametes breakdown in the macrogametes generating 
zygotes (9). The zygotes in turn become motile and extended (ookinetes) 
(10) and invade the midgut wall of the mosquito where they develop into 
oocysts (11). The oocysts grow, rupture, and release sporozoites (12), 
which make their way to the mosquito salivary glands. Inoculation of the 
sporozoites (1) into the new human host perpetuates the malaria life cycle. 
One of the most significant stages in malaria is when the parasite breaks 
up the host haemoglobin into free amino acids which the parasite utilizes 
for growth and development.[12] Most of the current anti-malarial drugs 
target the parasite food vacuole which is a special organelle for the 
digestion of the host haemoglobin.[13] 
1.1.2 Hemoglobin degradation in the food vacuole 
Haemoglobin is an abundant protein (95%) found in the erythrocytes, which 
plays the role of transporting oxygen and removal of CO2 from the 
tissues.[13] The degradation of haemoglobin in the food vacuole is believed 
to occur in a semi-ordered manner according to Fig. 1.4 & 1.5. A group of 
proteolytic enzymes, known as plasmepsins, falcipains and falcilysin are 
thought to mediate hemoglobin degradation. 
Globin (Fig.1.4) is sequentially degraded into small entities (amino acids) 











development processes.[12] The degradation occurs in a semi-ordered way 
such that there is a sequential action of different proteases.[14] 
Figure 1.4 shows how host hemoglobin is metabolised by the parasite to 
get nutrients for development and growth. Hemoglobin is transported from 
the parasite cytoplasm into the food vacuole where an aspartic protease, 
plasmepsin-1 degrades it into globin fragments. 
It has been shown that falcipain-2 and possibly falcipain-3 are also capable 
of digesting native hemoglobin and therefore participating in the initial 
cleavage of hemoglobin.[15,16] Other plasmepsins, plasmepsin-2 and 
plasmepsin-4, and the falcipains further degrade the globin fragments into 
polypeptides (up to 20 amino acids) which are further broken into small 
peptides (6 to 8 amino acids) by a metalloprotease, falcilysin. Small 
peptides are further degraded by aminopeptidases into amino acids outside 
the food vacuole (in the parasite cytoplasm).[17] 
Parasi te Cytoplasm 
Hemoglobin 
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The other portion of the haemoglobin degraded product, heme, is 











itself against the toxicity of heme. In the same vein, the parasite initiates 
degradation of heme by the following mechanisms: a) peroxides in the food 
vacuole, b) glutathione in its cytoplasm, c) heme oxygenase (this enzyme is 
only found in P. berghei and P. knowlesi but not in P. falciparum) in its 
cytoplasm.[18a] According to Tachezy,[18b] heme released from digested 
haemoglobin is rapidly sequestered into haemozoin; and the presence of 
heme oxygenase that mediates the release of iron in other cells was not 
found in Plasmodium spp. Elsewhere, it has been found that parasites that 
survived intracellularly in mammalians, such as Leishmania and malaria, 
could utilized mammalian holo-transferrin and / or holo-Iactoferrin as sources 
of iron.[18c] 
It has been proven that more than 95 % of heme is converted to 
hemozoin and the remainder is degraded as cited above. [18d] 
Thus, considering the mechanism that the parasite has developed for its 
survival, most of the anti-malarial drugs are designed to target the food 
vacuoleJ13] 
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With regard to this current project, designing a compound that will target 
the food vacuole like the current drugs would be of great interest since 
such a drug could be able to prevent the detoxification of heme or inhibit 
any other detoxification processes or stop the parasite from replicating by 
inhibiting the hemoglobin degradation process. 
1.2. Malaria Chemotherapy 
The World Health Organisation (WHO) submitted at the World Health 
Assembly in 1955 an ambitious proposal for the eradication of malaria 
worldwide. Eradication efforts began and focused on house spraying with 
residual insecticides, anti-malarial drug treatment and surveillance. Success 
including eradication in nations with temperate climates and seasonal 
malaria transmission have been witnessed in some countries such as India 
and Sri Lanka where the number of cases was dramatically reduced. Other 
nations had negligible progression (such as Indonesia, Afghanistan, Haiti 
and Nicaragua). However, most of sub-saharan Africa was excluded 
completely from the eradication campaign at that time.[19] 
Afterwards, the eradication campaign was abandoned due to many reasons 
including widespread resistance to available insecticides, drug resistance, 
wars, massive population movements, as well as difficulties in obtaining 
unceased funding from donor countries and lack of community 
participation. [19] 
At present, chemotherapy remains the only keystone to malaria control.[20] 
Thus, in the battle to discover an effective chemotherapeutic agent, a 
number of drugs have been discovered. Unfortunately most of them are 
faced with resistance from the parasite, while others have serious side 
effects that make them unfavourable towards humans. 
Some of the drugs that have been used for malaria control are discussed 












It is generally accepted that this category of anti-malarial drugs interfere 
with the detoxification of free heme, which is generated during hemoglobin 
degradation.[18a,22] There is evidence that 4-aminoquinoline drugs inhibit both 
malaria pigment (hemozoin) formation and the oxidative and glutathione-
dependent heme degradationY3] In this category of anti-malarial drugs, 
chloroquine 1 (Fig.1.6) is the most important due to it's great impact in the 
field of current anti-malarial drugs. 




Figure 1.6: Chemical structures of chloroquine 1 and amodiaquine 2 
Chloroquine was discovered by a German scientist, Hans Andersag, in 
1934 and was known by the name of resorchin at the time. It was not 
used at that time because it was considered to be toxic, until in 1946 when 
the drug was recognized by British and USA scientists. Since then, 
chloroquine has been the mainstay of anti-malarial chemotherapy. 
Chloroquine is a very potent schizonticidal and an effective drug against the 
erythrocytic stage for all Plasmodium species. It is a weak uncharged 
base at neutral pH, while it is a di-cation at acidic pH. Based on this 
property chloroquine selectively accumulates inside Iysosomes. The charged 
compound rapidly diffuses through the plasma and lysosomal membranes 
and, once charged the compound becomes trapped inside the acidic 











accumulates in the food vacuole to several orders of magnitude resulting 
from a concentration gradient. 
Digestion of hemoglobin takes place inside the plasmodium food vacuole 
resulting in the generation of free haeme (ferriprotoporphyrin IX) which is 
insoluble and precipitates in the form of hemozoin in the food vacuole. 
Though not clearly known, it is postulated that chloroquine in the food 
vacuole interferes with pigment (hemozoin) formation and also the 
ferriprotoporphyrin-chloroquine complex is highly toxic to the parasite.[24a, 24b] 
These two are known chloroquine mechanisms in the food vacuole. Other 
mechanisms were proposed such as inhibition of heme-dependent protein 
synthesis,[25] prevention of iron release from hemoglobin[26] and inhibition of 
food vacuole cysteine proteases.[27,28] 
Chloroquine effect on the parasite is so rapid comparatively to others and 
it is less toxic to the subject. This drug is admistrated to everyone even 
to pregnant women,l21] Its effect on the parasite is very rapid compared to 
other drugs. Sometimes patients can experience headaches, nausea, 
vomiting and gastrointestinal symptoms while taking the drug. In spite of the 
efficacy of chloroquine, the malaria parasite has developed resistance 
towards the drug. The first case was noted in the late 1950's from 
Colombia and Thailand. Reports of similar resistance patterns quickly 
followed from other countries in South America and South East Asia. The 
first clearly documented case of chloroquine-resistance P. fa/ciparum was 
reported from Kenya in 1979 in a tourist.[29] Nowadays, chloroquine-
resistant is prevalent in most P. falciparum-endemic areas of the world, 
causing the use of chloroquine for presumptive treatment of P.fa/ciparum 
malaria or chemoprophylaxis to be inappropriate. [30] 
Amodiaquine 2 (Fig.1.6) is another 4-aminoquinoline drug. It was introduced 














As with chloroquine, amodiaquine is an anti-malarial with schizonticidal activities. 
It is effective against the erythrocytic stages in all the Plasmodium species 
except mature gametocytes of P. falciparumY1] It accumulates in the 
Iysosomes and brings about loss of function and the parasite becomes 
unable to digest hemoglobin on which it depends. Various serious adverse 
effects were experienced with administration of the drug including nausea, 
vomiting, skin rash and pruritus. Its administration is not advisable to 
pregnant and breastfeeding women. Nowadays, amodiaquine is no longer 
recommended alone due to the risk of severe advert reactions such as 
agranulocytosis and hepatotoxicity. 
1.2.2. B-Aminoquinolines 
Primaquine 3 and Tafenoquine 4 (Fig.1.7) belong to the 8-aminoquinoline 
class of anti-malaria Is. Primaquine is highly effective against the 
gametocytes of all malaria parasites and prevents spread of the disease to 
the mosquito from the patient. It is commonly used in areas with low or 
moderate malaria transmissionY1,32] It is also active against hypnozoites of 
the relapsing malarial parasites, P. vivax and P. ova/e.[33] It reported to be 
active against asexual blood stages of P. falciparum in Thailand.[32,34] 
Primaquine 3 
Tafenoquine 4 











The mechanism of action of primaquine is not clear yet but it was 
suggested that it may act by generating reactive oxygen species or by 
interfering with the electron transport in the parasiteY1] 
Primaquine is tolerable at therapeutic dosage but at higher dosages it may 
cause occasional epigastric distress and abdominal cramps, mild anemia, 
cyanosis, methemoglobinemia in some patients. Toxicological concerns have 
led to restrictions in the use of primaquine.[35] For this drug there is no 
specific antidote and treatment is only symptomatic. 
Tafenoquine 4 (Fig.1. 7) is a long-acting 8-aminoquinoline anti-malarial with a 
half-life of 2 weeks. The drug is used by short-time visitors to malaria 
areas to prevent the risk of P.fa/ciparum malaria infectionsY6] It is 
frequently used for treating multidrug-resistant P.fa/ciparum, and in 
combination with artemisinin derivatives gives good results. 
The major disadvantage of 8-aminoquinoline drugs is that patients with 
deficiency of glucose 6-phosphate dehydrogenase (G6PD) are not advised 
to take the drug because they are likely to develop hemolytic anemia on 
taking usual doses (up to 0.25mg/kg/day and 15mg/day/adult)Y7] 
1.2.3. Aryl Amino Alcohols 
Quinine 5 (Fig.1.8) is the chief constituent of the tree cinchona /edgenaria 
(known as "fever bark") found in South America. Quinine was isolated in 
1820 from the cinchona tree by Pelletier and CaventouY1] Nowadays, 
















CF3 Halofantrine 7 
Quinine 5 Mefloquine 6 
tC60' C /0 '-':: '-':: I ~ / N 
Quinidine 8 
Figure 1.8: Chemical structures of quinine 5 ,mefloquine 6, halofantrine 7 
and quinidine 8 
Quinine, like chloroquine is a schizonticidal drug. Besides its schizonticidal 
activity against the 4 Plasmodium species, it also has gametocytocidal 
activity against P. vivax and P.malariae.[21] 
Quinine is less effective, less tolerable and more toxic than chloroquine. 
Toxicity of quinine results from repeated doses while adverse effects 
including tinnitus, progressive loss of auditory acuity, blurred vision, 
photophobia, rashes, sweating, nausea have been reported in larger doses. 
Massive hemolysis and hemoglobinuria can occur, especially in pregnant 
women or on repeated use. This drug is only recommended in places 
where severe P.falciparum malaria resistance towards chloroquine has 
been reported. It is used as an intravenous formulation in severe malaria 











Mefloquine 6 (Fig.1.8) was discovered during the Vietnam war as a result of 
research into newer anti-malarials to protect American soldiers. It is 
chemically related to quinine. It is a potent long-acting blood schizonticide 
active against P.fa/ciparum resistant to 4-aminoquinolines. It is also highly 
active against P. vivax and P.ma/ariae, and most probably P. ova/e. 
Mefloquine is not gametocytocidal, and is not active against the hepatic 
stages of malaria parasites.[32J In terms of the mode of action, mefloquine 
has been found to produce swelling of the P. fa/ciparum food vacuole and 
it also may act by forming toxic complexes with free heme that end up 
damaging the parasite membrane and other plasmodial componentsY1J 
Mefloquine is recommended as a prophylactic drug for travelers to areas 
with significant risk of chloroquine-resistant P.fa/ciparum malaria. 
Neuropsychiatric adverse reactions have been reportedly associated with 
mefloquine use including affective disorders, anxiety disorders, hallucinations, 
sleep disturbances, toxic encephalopathy, convulsions and acute brain 
syndromeys-4oJ The drug is not recommended to persons with an allergies 
to it, of severe neuropsychiatric disease and to persons performing activities 
requiring fine coordination and spatial discrimination (e.g. air pilots and 
machine operators). 
Halofantrine 7 (Fig.1.8) is a blood schizonticidal against all malaria parasites. 
It is active against P.fa/ciparum infections that are resistant to chloroquine 
1.[21J The drug is not recommended to people with a history of heart 
disease.[41J 
Quinidine 8 (Fig.1.8) is a diastereoisomer of quinine with similar anti-malarial 
properties. It is slightly more effective than quinine but has a greater 
cardiosuppressant effect.[42J With respect to the toxicity and drug interaction, 











drug for parenteral treatment of severe malaria and may be used instead 
of quinine in patients with uncomplicated malaria. 
1.2.4. Folate Antagonists 
This category of anti-malaria Is affects the synthesis and utilization of 
folate. Proguanil 10 and pyrimethamine 11 (Fig.1.9) act by inhibiting 
dihydrofolate reductase, which is necessary for the synthesis of 
tetrahydrofolate, a precursor in the parasite DNA synthesis.[43,44] 
Sulphonamides (e.g. sulfadoxine 12) and sulphones (e.g. dapsone 9) (Fig.1.9) 
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~NI(NI(Ny 
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Proguanil 10 
Sulfadoxine 12 
Figure 1.9: Structures of Folate antagonist anti-malarials. 
Pyrimethamine 11 
Proguanil is a well tolerated drug that is commonly used in combination 
with chloroquine due to its low efficacy if used as a monotherapeutic 
agent.[45] 
These folate antagonists act on erythrocytic P.falciparum by a mop up 
system after treatment with quinine in an acute attack of chloroquine 
resistant P.falciparum malaria parasites. Large doses of pyrimethamine-












Atovaquone 14 (Fig.1.10) is a naphthoquinone derivative that is structurally 
analogous to coenzyme Q (ubiquinone) found in the mitochondrial electron 
transport chain. This drug disturbs parasite biochemical processes by acting 
against ubiquinol-cytochrome c oxido-reductase, inhibiting electron transport 
and collapsing mitochondrial membrane potential.[47J 
A combination of atovaquone and chloroproguanil 13 (Fig.1.1 0) is used both 
for treatment and prophylaxis of malaria, and it has been proven to be 
highly efficacious in the treatment of uncomplicated malaria in areas with 
chloroquine-resistant or multidrug-resistant strains. [21J 
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Figure 1.10: Chemical structures of chloroproguanil13 and atovaquone 14 
1.2.6. Antimicrobials 
Certain antimicrobial drugs are useful in the treatment of drug resistant 
P. falciparum malaria. They act relatively slowly and for that reason they 
are applied as prophylactics or combined with faster acting drugs like 
quinine or pyrimethamine for effective cure. 
Tetracycline 15 (Fig.1.11) is a bacteriostatic agent, which supposedly 
acts by inhibiting protein synthesis by binding to the 30s ribosome 
subunity1J 
Another antimicrobial, doxycycline 16 (Fig.1.11) is the most frequently used in 
anti-malarial chemotherapy, either alone as a prophylactic or in combination 
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Doxycycline 16 
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Figure 1.11: Chemical structures of tetracycline 15 and doxycycline 16 
1.2.7. Endoperoxides 
Artemisinin 17 (Fig.1.12) an endoperoxide anti-malarial and its 
derivatives (artemether 18, artesunate 19 and arteether 20) (Fig.1.12) are the 






Figure 1.12: Chemical structures of artemisinin 17 and its derivatives 18, 19, 20 
Artemisinin was isolated in 1971 from the Chinese medicinal herb 
artemisia annua used in the treatment of fevers in China.[21] 
Artemisinin derivatives have been developed for the treatment of cerebral 
malaria as well as for the control of multidrug-resistant P. falciparumY1] 
The artemisinins are active against the sexual parasite stages 
(gametocytes), which are responsible for the infection of the anopheles 
mosquito and for transmission of the disease,[47] and they are also 
effective against the chloroquine-resistant strains of P.falciparum.[21] However, 
these expensive drugs are associated with high incidences of 
recrudescent infection if used alone, therefore it is suggested that the 











one of the controversial mechanisms, the biological activity of artemisinins 
is believed to depend on the cleavage of the peroxide bond after contact 
with Fe" heme inside the food vacuole (Fig.1.5), thus generating free 
radicals that can alkylate the heme molecule.[48] A number of other 
mechanisms for artemisinin and related compounds have been proposed.l49] 
1.2.8. Iron Chelators 
Oesferrioxamine (OFO) 21 (Fig.1.13) is the only iron chelator that is used 
against malaria in vivo. It is a naturally occurring trihydroxamic acid, a 
siderophore produced by Streptomyces pi/osus.[50] 
o 0 
"N~N~N0 
H OH OH 
o OH 
/lN~N~NOH 
OH 0 0 
Desferrioxamine 21 
Figure 1.13. Structure of desferrioxamine 21 
When given as a single agent, OFO suppresses the growth of P. fa/ciparum 
in parasitized erythrocytes by chelating a pool of iron associated with the 
parasite.[51] OFO could also enhance the host immune response.[50] The 
clear mode of action of OFO is still debatable. Some side effects are 
associated with this drug such as kidney function decrease, fever (pyrexia), 
blood disorders, asthma, hearing disturbances and visual disturbances.[43] 
Based on the above succinct description of different drugs, their mode of 
actions and the associated drawbacks, it gives a clear image that there is 
not yet an effective drug that would tackle this health threatening 
disease, malaria, to effectively replace chloroquine. Therefore, doors are still 
open for any potential drug that will be effective, accessible and also that 
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IRON CHELATORS AS ANTI-MALARIALS 
2.1. Iron 
Iron is the second most abundant metal on the earth's surface, falling 
closely behind aluminium and in near equivalent concentration to calcium 
and sodium.[1] The concentration of iron (Fe) in the human body is 
estimated to be about 40-50 mg/ kg for men and less than that for 
women. Most of this (about 80%) is located in the oxygen transport storage 
proteins hemoglobin and myoglobin.[2] 
Iron is a critically important metal for a wide variety of cellular eventsY] 
It is an essential element for the growth of almost all microorganisms, 
with the notable exception of non- pathogenic lactobacilli.[3] It is used in the 
catalysis of DNA synthesis and in a variety of enzymes concerned with 
electron transport and energy metabolism.[1] It also plays a role in the 
reduction of ribonucleotide[4,5] to deoxyribonucleotide which is the rate-
limiting step for DNA synthesis, and the activity of the enzyme 
ribonucleotide reductase (RR) is iron-dependent. The iron centre in RR 
stabilizes a tyrosyl radical within its R2 subunit.[4,5] 
Molecules with nitrogen, oxygen and sulfur donor atoms avidly bind Fe. The 
Fe-N bonds in the porphyrin ring of heme proteinase are key to their 
function as efficient oxygen transport and storage molecules. [6] Additionally, 
Fe plays a role in activation and decomposition of peroxides. [1] 
Like all living organisms, malaria parasites need iron for vital cell functions 
and it has been found that Fe (III), Fe3+, is the one involved in the intra-











Egan et al [9] have shown that P. falciparum trophozoites contain 61 ± 2% of 
the iron within parasitized erythrocytes, of which 92 ± 6% is located within 
the food vacuole. Of this, 88 ± 9% is in the form of hemozoin. 
The acquisition of iron by the intra-erythrocyte parasite has been 
suggested as follows: The merozoite enters the erythrocyte by attaching to 
sialic acid residues on the red blood cell surface.[10] Within the red blood 
cell, the parasite first appears as a ring form and matures into a 
trophozoite. The parasite, by some process, enhances the host red blood 
cell permeability[11] and then the trophozoite ingests the host cell 
cytoplasm, including hemoglobin, by means of a cytostome to get 
nutrients[B] or may take up molecules from the outer medium directly via 
the parasitophorous duct.[12] Once taken up into the parasite, host 
cytoplasm is transported in vesicles to the food vacuole (site of primary 
hemoglobin proteolysis) where aspartic proteases (plasmepsin I and II) cleave 
the hemoglobin into small peptides.[13] 
2.2. Potential Sources of Fe for the Malaria Parasite 
Iron being important to almost all microorganisms including the malaria 
parasites, one has to ask: where do parasites get iron from? Although 
there are some doubts about the source of iron for the parasite growth, 
some researchers think that there is a possibility that a small amount of 
heme degraded in a controlled way in the food vacuole could release Fe 
for the metabolic processes of the parasite.[14] This is just a small amount 
of Fe that the parasite might use in the process. There is less information 
on the means by which protozoa, including malaria parasites, acquire iron 
to sustain their growth. Some potential sources of iron for the parasite use 











2.2.1. Plasma transferrin-bound iron 
Some studies suggested that plasma transferrin (iron transport protein) may 
be one of the sources of Fe for the parasite. Through clinical studies, it 
has been found that the protection of Fe deficiency against human malaria 
and increased Fe uptake through daily nutrition improved responsiveness 
to malaria infection[15-17] and the expression of transferrin receptors by 
mature parasitized red blood cells has been reported. [18,19] 
Later, however, some clinical and experimental evidence proved that human 
Fe does not affect malaria infection[20] and no transferrin receptors exist on 
parasitized erythrocyte.[20,21] 
Many arguments have arisen about transferrin being amongst the sources 
of Fe for the parasite but the overall evidence indicates that transferrin Fe 
is not taken up by the parasitized red blood cells.[22,23] 
2.2.2. Erythrocyte Ferritin 
It has been found that the mature erythrocyte is incapable of synthesizing 
its own ferritin, Fe storage protein, but it contains some residual ferritin 
which was produced during the earlier erythroblast phase.[24] This residual 
ferritin was found to contain about 4.5 IJM Fe if fully concentrated.[19] 
The acquisition of Fe by the parasite within the parasitophorous vacuole 
from ferritin in the cytoplasm of the erythrocyte is not yet experimentally 
proven. Nevertheless ferritin traces have been detected in subjects deficient 
in Fe[25] and the possibility exists for the parasite to take up iron from 
ferritin across the parasitophorous vacuole membrane and parasite plasma 
membrane, or through the process of cytostosomal ingestion and transport 











In contrast to early statements, Fe deficiency was found to be associated 
with low red blood cell ferritin concentrations[25] without inhibition of intra-
erythrocytic parasite growth.[22] 
2.2.3. Host hemoglobin 
A great portion of the amino acids that are necessary for protein synthesis 
comes from the host hemoglobin catabolism process which is mainly used 
by the intraerythrocytic parasite. [13,26,27] The heme released from the 
process is known to contain significant amounts of Fe and might be 
available for the parasite's metabolic needs, if liberated. [28] 
While evidence that the parasite uses the Fe derived from host heme is 
missing, it is likely that a small amount of heme in the food vacuole is 
degraded to liberate Fe for the metabolic processes of the parasite.[13] 
Elsewhere, it was proven that the parasite might also utilize a non-heme 
source of Fe. [20,29] 
2.2.4. Intra-erythrocyte iron pool 
Some studies done on hemolysates of rat cells parasitized with P.berghei 
have revealed that there is a labile pool of Fe that is chelatable by 
preincubation of the intact cells with an Fe chelator such as DFO 
(Desferrioxamine).[22] Elsewhere, two studies have shown that there is no 
inhibition of the plasmodial growth when Fe chelator agents were 
introduced into the cytoplasm of erythrocytes specifically but not into the 
parasite compartment within the parasitophorous vacuole. [25,29] It is possible 
that the parasite uses both host labile iron and host hemoglobin iron as a 
source of Fe. Therefore the abrogation of only one will not prevent 
parasite growth. 
Since the source of Fe for the parasite is not yet well-known, the fact 











development like all living organisms.[2,30] Many enzymes of the intra-
erythrocytic malaria parasite are Fe-dependent. The table below (Table 1) 
shows a list of different malaria parasite enzymes that are Fe-dependent 
and their respective pathways. 
Table 2.1: Fe-dependent enzymes and their metabolic pathways 
Metabolic pathway Enzymes Reference 
DNA synthesis Ribonucleotide reductase 31,32 
Pyrimidine synthesis Dihydrorotate dehydrogenase 33, 34 
Glycolysis Glycolytic enzyme 35, 36 
Pentose phosphate shunt Pentose phosphate shunt enzyme 37 
CO2 fixation Phosphoenol pyruvate carboxykinase 31 
Proteolysis of hemoglobin Proteolytic enzymes 38 
Heme synthesis o-aminolevulinate 39 
Mitochondrial electron Cytochrome oxidase 34,40, 
Transport 41 
2.3. Iron Chelators 
Fe chelators have been used to remove excess Fe in the body in 
thalassemia patients because the human body has no efficient ways to 
excrete excess Fe accumulated. [42] Fe chelators display other interesting 
medicinal properties apart from removal of Fe from the body including 
anti-cancer properties,[43] photoprotective properties,[44] anti-asthma 
properties,[45] anti-HIV properties in conjunction with HIV-protease or reverse 
transcriptase inhibitors[46] anti-hydroxyl radical formation,[47] anti-
neurodegenerative properties[43.47,48] as well as anti-malarial properties.[14,43] 
As far as this Msc project is concerned, focus will be placed on iron 











In the process of finding a way of eliminating malaria or decreasing its 
fatality, researchers have hypothesized that depriving the malaria causative 
agent, P. fa/ciparum, of Fe might have some implications in the metabolic 
pathways of the parasite regarding the role of Fe in malaria parasite 
growth and proliferation. [32,49] Therefore, inhibiting the parasite could be one 
of the routes to effective antimalarial therapy. 
2.3.1. Mode of inhibition of malaria parasites by antimalarial iron 
chelators 
There are two known major modes by which Fe chelators deprive malaria 
parasites of Fe, therefore inhibiing the parasite growth.[50] 
i) Withholding Fe from malaria parasite metabolism. The mechanism of 
antimalarial action of this class of iron chelators appears to be the 
sequestration of iron for plasmodium replication. This class of molecules 
with this mode of action include the following: hydroxamate siderophores 
(e.g. DFO), catecholamide and catecholate siderophores (e.g.Gamma Amino 
Butyric Acid), a-ketohydroxypyridinones (e.g. Deferiprone), dihydrocoumarins 
(e.g. Daphnetin), and bis-cyclic imides (Dexrazoxane) (Fig.2.1). 
The anti-plasmodial action of DFO is related to its interference with DNA 
synthesis presumably via inhibition of ribonucleotide reductase, RR.[32, 51] 
Eukaryotic ribonucleotide reductase, including the P. fa/ciparum enzyme, 
contains two a and two ~- subunits.[52] The two dimers a2 and ~2 are 
known as protein B1 and protein B2 respectively. B2 contains an essential 
tyrosyl radical that is stabilized by an adjacent dinuclear iron centre and is 
thought to initiate the radical-based reaction of ribose into deoxyribose.[4,5] 
The intracellular Fe in the labile Fe pool is in equilibrium with the Fe in 
the dinuclear Fe centre.[53] DFO chelates the intracellular Fe, which 
indirectly impacts on the dinuclear iron centre. Thus, it inhibits 











regeneration of Fe radical centre.[54] This leads to the DNA synthesis 
inhibition and eventually the death of the parasite could occur. 
ii) Complexing with Fe to form a complex that is toxic to the parasite. This 
class of compounds seem to have an antiparasitic effect other than the 
withholding of iron. Agents that inhibit parasite growth by forming toxic 
complexes with Fe are represented by 8-hydroxyquinoline (Fig. 2.1). It 
appears that the 8-hydroxyquinoline-Fe complex is formed extracellularly, 
which subsequently enters the parasitized red blood cell to produce a 
rapid lethal free radical-mediated intracellular reaction. 
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Figure 2.1 : Structures of antimalarial iron chelators. 
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FERROCENIC COMPOUNDS IN CHEMOTHERAPY-
AIMS AND OBJECTIVES OF THIS RESEARCH 
3.1. Introduction 
31 
Ferrocenic compounds are those containing the ferrocene moiety 22 
(Fig.3.1) within their structure. Ferrocene comprises two cyclopentadienide 
ligands coordinated to Fe in the +2 oxidation state; it was reported for the 
first time in 1952.[1,2] The suggested structure of ferrocene was provided by 
Wilkinson[3] and Fischer[4] separately afterwards. The name ferrocene was 






Figure 3.1: Structure of ferrocene 22 
The discovery of this new organometallic compound has brought about 
the starting point for modern organometallic chemistry,[1] and the growth of 
bioorganometallic chemistry which links classical organometallic chemistry to 
biology, medicine, and molecular biotechnology. [6-8] 
Today ferrocene and its derivatives are popularly used in various biological 
applications and for conjugation with biomolecules because of ferrocene's 
unique properties such as low reported toxicitY,[9,10] stability in aqueous and 
aerobic media, high lipophilicity (logPoctanoliwater= 3.28), accessibility of its 











properties.[11] Ferrocene itself is reported to exhibit anti-anemic 
properties. [12.13] 
3.2 Ferrocenic Compounds 
3.2.1 Ferrocenic Compounds as Antimycobacterial Agents 
The ferrocenyl diamines 23 and 24 (Fig.3.2) have been synthesized as 
potential inhibitors of Mycobacterium tuberculosis, the causative agent of 
tuberculosis.[14] Out of the compounds synthesized, ferrocenyl diamines 23 
and 24 were shown to possess greater activities with the most active 
compound having an ICso value of 8 iJg/ml against M. tuberculosis H37Rv 
strain.[14] 
Replacement of the ferrocenyl moieties in 23 and 24 to generate the 
phenyl-substituted diamines 25 and 26 (Fig.3.2) resulted in a four-fold 





23: n= 2 
24: n=3 
~N4N~ V H H V 
25: n=2 
26: n=3 
Figure 3.2: Chemical structures of ferrocenyl diamines 23 and 24, and 
their phenyl derivatives 
This suggests an important role for ferrocene in the antimycobacterial 
activity of diamines 23 and 24. 
3.2.2. Ferrocenic compounds as Antifungal Agents 
Fluconazole 27 (Fig.3.3) is a triazole antifungal agent which inhibits specific 











particularly against opportunistic yeasts of the genus Candida.[15] Candida 
species (i.e. C. albians, C. glabrata, C. parapsilosis, C. kruse/) are the fifth 
most common isolates in hospital environments. Fluconazole is considered 
to be a useful agent for managing patients at risk of these infections.[16] 




F ~N~ \N~N \ N 
';--N N~ -::J N::d 
N I \ N 
N HO \:::::::N OH N::::::J 
27 28 
Fc= ferrocene 
Figure 3.3: Fluconazole 27 and ferrocene-fluconazole 28 
Ferrocene-fluconazole (28) is a derivative of fluconazole in which the 
aromatic ring was replaced by a ferrocenyl group. The introduction of 
ferrocene in fluconazole resulted in a reversal effect on the resistance of 
the fungi. This was assumed to be an effective way of overcoming 
fluconazole resistance in the yeast. [16] 
3.2.3. Ferrocenic Compounds as Anticancer Agents 
Tamoxifen 29 (Fig.3.4) is a drug used in the treatment of hormone-
dependent breast cancers via its active metabolite, 4-hydroxytamoxifen 30 
(Fig.3.4),[19a.19b] which is considered as the archetypical SERM (Selective 
Estrogen Receptor Modulator). Replacement of the aromatic ring on 
tamoxifen 29 and 4-hydroxytamoxifen 30 with a ferrocenyl moiety gives 
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Figure 3.4: Structures of tamoxifen 29, hydroxytamoxifen 30 and their ferrocene 
derivatives 31 and 32, respectively. 
34 
It has been shown that hydroxyferrocifen 32 displays superior activity 
compared to its phenyl counterpart, compound 32. Hydroxyferrocifen has 
shown antiproliferative effects on both hormone-dependent (MCF7) and 
independent (MDA-MB231) breast cancer cell lines in vitro whereas its 
phenyl counterpart 30 is active only against hormone-dependent cell 
linesYO] 
3.2.4. Ferrocenic Compounds as Antimalarial Agents 
The antimalarial activities of ferrocenic compounds has been the most 
studied to date. Several well-established antimalarial drugs have been 
coupled covalently to a ferrocene entity resulting in general improvement 
in activity.[21] 
The well-established drug, chloroquine, has experienced varying degrees of 











resistance, new approaches have been developed including the 
incorporation of a ferrocenyl group into a chloroquine molecule. This has 
led to the development of Ferroquine 33. This compound 33 (Fig.3.5), a 4-
aminoquinoline derivative in which the two methylene groups in the side 
chain of chloroquine have been replaced by a Ferrocenyl moiety, has 
been synthesized and found to be active against both chloroquine-resistant 
and sensitive strains of the malaria parasite at low concentrations, in 
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Figure 3.5: Structures of ferroquine 33 and chloroquine ferrocene carboxylic 
acid salt 34 
The efficacy of chloroquine decreased when the ferrocene entity was not 
covalently bound to the chloroquine (as in ferroquine), as exemplified by 
compound 34. (Fig.3.5) 
The low antiplasmodial activity of 34 amongst others demonstrated that the 
ferrocene molecule needs to be bound covalently to chloroquine to reverse 
chloroquine-resistance in the parasites, and that ferrocene by itself does not 
have significant anti-malarial activity. [211 
In the process of looking for other ways of incorporating ferrocene into the 
structure of chloroquine, compound 35 (Fig. 3.6) was synthesized and found 
to reverse chloroquine resistance in the malaria parasite (HB3, Dd2, FG1, 











increased cellular accumulation and also increased lipophilicity brought 
about by the presence of the substituted ferrocene. [22] 
35 36 
Figure 3.6: Ferrocene derivative salt 35 and ferroquine salt 36 
A salt derivative of ferroquine was synthesized in order to investigate if 
the solubility has an impact on the antimalarial activity of the ferroquine. 
The inhibitory concentration (ICso) of both the ferroquine salt 36 (Fig.3.6) 
and ferroquine 33 were similar.[21] 
The strategy for the synthesis of new ferrocene-chloroquine analogues 
particularly replacing the carbon chain of chloroquine by a ferrocenyl moiety 
was also extended to the anti-malarial amino-alcohols such as mefloquine 
and quinine. This led to new analogues of quinine and mefloquine 37 and 















Ferrocenic quinine analogue 37 is an amino-alcohol derivative in which the 
quinuclidinyl group was replaced by a substituted ferrocenyl moiety and 
ferrocenic mefloquine analogue 38, is also an amino-alcohol derivative in 
which the piperidinyl group of mefloquine was replaced by the ferrocenyl 
mOiety and unfortunately these compounds were found to have lower 
antimalarial activity than mefloquine or quinine on all P. fa/ciparum strains 
used.[23] 
Other ferroquine analogues were synthesized in which Fe of the ferrocenyl 
mOiety was replaced by ruthenium (Ru) (structures shown in Figure 3.8) and 
tested against the malaria parasite resistant K1 strain and sensitive 010 
strain. Compared to ferrocene, these ruthenocenes did not show essential 
difference in terms of the antimalarial activity.[24] 
39a 39b 
40a 40b 
Figure 3.8: Chemical structures of ferroquine analogues 39a-b, 40a-b. 
The probable mechanism of ferroquine on malaria parasite has been to 
some extent studied and discovered to be likely similar to that of 











inhibition of hemozoin formationY5] The lipophilic character of ferrocenyl 
moiety present in ferroquine has been found to be one of the contributors 
to activity of the compound. This physical property presumably allows the 
toxic drug to be maintained within the vacuoleY5] 
Moreover, ferrocene has been proposed to block PfCRT (P. falciparum 
Chloroquine Resistance Transporter) through its lipophilic properties like a 
resistance reversing agent.[25] PfCRT is a transmembrane protein which 
localizes to the parasite digestive vacuole, the site of chloroquine action. 
3.3 Aims and Objectives of this Msc Dissertation 
3.3.1 Objectives 
The overall objective of this Msc project was to incorporate a ferrocene 
unit into the structure of metal (iron) chelating thiosemicarbazones and to 
study the electrochemical behaviour of the resulting molecules with a view 
to exploring any correlation between redox behaviour and antiparasitic 
activity. 
3.3.2 Specific aims and rationale of the project 
1. Synthesis and structure activity relationship study of new ferrocenic 
metal chelating thiosemicarbazones 41 and 42 (Fig. 3.9) as potential 
antiprotozoal agents. 
Thiosemicarbazones were selected due to their known multiple 
biological activities including antibacterial and antiviral,[26,27] anticancer, 
[28] antiplasmodial[29] and antitrypanosomal[30] properties. 
The known lipophilicity of ferrocene was envisaged to render 
ferrocenic thiosemicarbazones lipophilic. Lipophilicity is important in 











by chelators from P. falciparum most likely resides within the parasitic 
compartment of the malaria infected red blood cell. Thus, chelators 
have to cross the malaria parasite membranes to reach to the 
presumed site of action where selectivity is required for iron 
compared to other endogenous metals.[31] 
2. Biological evaluation, in collaboration with appropriate laboratories, of 
the synthesized thiosemicarbazones against both chloroquine-sensitive 
and chloroquine resistant strains of the causative agent P. falciparum 
as well as against Trypanosoma brucei, the causative agent for 
African sleeping sickness or trypanosomiasis. 
3. Electrochemical (cyclic voltammetric) evaluation of the synthesized 
ferrocenic thiosemicarbazones. 
The ferrocenyl group is particularly well-behaved electrochemically, 
providing a reversible one-electron couple. Thus we reasoned that 
studying the electrochemical behaviour of the synthesized ferrocenic 
thiosemicarbazones in conjunction with biological activity evaluation 
might provide insight into possible correlation between redox 
behaviour and biological activity. If correlation between redox 
behaviour and biological activity could be established, cyclic 
voltammetry might be used as an analytical pre-selection tool for 
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RESULTS AND DISCUSSION 
42 
In this chapter the synthesis and characterization of ferrocenic 
thiosemicarbazones and their intermediates are detailed. This is followed by 
electrochemical studies of selected ferrocenic thiosemicarbazones. The 
biological results of both the intermediate thiosemicarbazide thioesters and 
target ferrocenic compounds are presented and discussed. 
4.2. Chemistry 
4.2.1 Retrosynthetic analyses 
The N-substituted ferrocenic thiosemicarbazones 41 and 42 could be made 
from two different methods as depicted in schemes 4.1 - 4.4. 
R ~N~ H r~~ J< /~ ~J ? I C-N > H2N/Nn\N~ 6 
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Scheme 4.2:Retrosynthetic analyses of N-substituted ferrocenic thiosemicarbazone (Meth. 1). 
















































Scheme 4.4: Retrosynthetic analyses of N-substituted ferrocenic thiosemicarbazone 
(Meth. 2). 
44 
The retrosynthetic analyses depicted in schemes 1 and 2 identify ferrocene 
carboxaldehyde 45, piperazine and hydrazine thioester 43 as key starting 
materials. Method 2 as depicted in scheme 4.3 and 4.4 was judged to be 
more convenient as we were interested in evaluating the biological 
activities of the intermediate thioester. 
4.2.2 Synthesis of thiosemicarbazone thioesters 
The substituted thiosemicarbazone thioesters were synthesized from a 











available) and synthesized hydrazine thioester 43, scheme 4.5. Compound 
43 was synthesized from commercially available hydrated hydrazine 
(NH2NH2), carbon disulphide (CS2) and methyl iodide (CH31) according to a 








Scheme 4.5: Reagents and conditions: (a) CH30H, ambient temperature, 20 h. 
1H NMR spectroscopy was used to confirm the proposed structures of 
thiosemicarbazone thioesters in all cases. The 1H NMR of synthesized 
compounds showed a singlet integrating for 3 hydrogens at ca 0= 2.6 ppm 
corresponding to the SCH3 group (Fig. 4.1 and Fig. 4.2). A singlet was 
observed at ca 0= 2.3 ppm for methyl ketone-derived thiosemicarbazone 
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Figure 4.2: 1H NMR spectrum of 44a a typical ketone-derived thiosemicarbazone 











The 13C NMR data confirmed the exact number of carbon present in the 
synthesized molecule. At around 198 ppm, for most of them, the peak for 
thione carbon which confirmed the successful synthesis of the 
thiosemicarbazone thioester was observed. The infrared analyses showed, 
for all the thiosemicrabazone thioesters, absorbance peaks at around 3020, 
1420, 1213 and 770, 666 characteristics of amine (N-H), imine (N=C), 
thione (C=S) and aromatic protons (C-H), respectively. 
The mass spectrommetry value, for each thiosemicarbazone thioester, was 
consistent with the calculated molecular weight for each synthesized 
molecule. 
The 1H NMR spectrum of the 2-acetylpyridine-derived thiosemicarbazone 
thioester (Fig. 4.4) showed a mixture of geometrical isomers in deutero-
chloroform (COCI3) as described in the literatureYJ The literature suggested 
that there are at least three isomeric forms (Z, E' and E). The E' isomer 
(Fig. 4.3) involves C=N-N=C(S-)N conjugation. In deutero-chloroform the 
intensity of E' is lower. It has been observed that in deutero-OMSO 
(OMSO-d6) a single hydrogen-bonded isomer is observed and that must be 
E'. 
" Cis" (Z) "Trans" (E) "Trans" (E') 
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Fig. 4.4: 'H NMR spectra of 2-acetylpyridine thiosemicarbazone thioester in 














Table 4.1: Isolated yields of thiosemicarbazone thioesters 
R H 
A /N~SMe 
Ar N II 
S 
Compounds Ar R % yield Compounds Ar R % yield 
y\ y\ 44a 1/ CH3 80 449 1/ H 64 
Br CI 
44b CC\ H 71 44h £(\ H 80 
/ Br CI 1/ 
44c ct H 71 44i ~\ 1 / CI / CH 3 92 
Br CI 
44d £(\ 11' 88 H 57 44j CI 1/ H Br / 
CI 
44e J:;J\ U\ H 71 44k CI 1/ H 88 1/ 
N02 











Table 4.1: Isolated yields of thiosemicarbazone thioesters (continued). 
% 
Compounds Ar R % yield Compounds Ar R 
yield 
y\ q\ 44m H 94 44t H3CO I ~ H 77 
OH 
OCH3 
~\ Vc\ 44n H 95 44u I~ H 82 
HO I / H3CO OCH3 
OCH3 
440 d H 75 44v £)\ H 94 HO / OH (H 3C)2 N I ~ 
c;x:\ N02 44p 
I/- OH H 57 
44w Cc\ H 92 
I / N0
2 OH 
44q y\ H 85 44x lX\ I /ON CH3 64 
OCH 3 
c Q(\ lX\ lX\ 44r I / OH H 64 44y I /ON I /ON 86 
OCH3 












4.2.3 Synthesis of ferrocenylmethyl amines 47 and 48, and 
synthesis of N- substituted ferrocenic thiosemicarbazones 
51 
This synthesis was carried out via two different methods. The first method 
involved the synthesis of ferrocene amine 47 which was synthesized from 
ferrocene carboxaldehyde 45 and hydroxylamine hydrochloride (NH20H.HCI) 
to generate ferrocene oxime 46[3] in 80% yield. Compound 46 was further 
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Scheme 4.6: Chemical synthesis of ferrocenyl methyl amines, 47 and 48 
The second method involved the synthesis of the piperazine-based 
ferrocenylmethyl amine 48 via reductive amination.[4] Thus, ferrocene 
carboxaldehyde was reacted with piperazine to generate an iminium ion in 
situ, which was subsequently reduced using NaCNBH3 to give the target 











The 1H NMR spectrum of 46 showed a singlet at 0= 8.0 ppm corresponding 
to one proton of the azomethine and a broad singlet at 0= 7.5 ppm due 
to the OH group of the oxime which disappeared after reduction to 47. 
The 1H NMR spectrum of 47 showed a singlet at 3.54 ppm integrating for 
two (CH2) protons. In addition to this, the broad singlet observed at 7.5 
ppm in the 1 H NMR spectrum of 46 and assigned to the OH group of the 
oxime disappeared. The 1H NMR data of both 46 and 47 were consistent 
with the IiteratureJ3] 
The synthesis of thiosemicarbazones[5] was a straight forward substitution 
reaction between selected ketone and/or aldehyde-derived 
thiosemicarbazone thioesters in MeOH under reflux. The results are 
presented in Table 4.2. 
S H 
AryN'NJl-NQ 
R H ,0 










Table 4.2: Isolated yields of synthesized N-substituted Ferrocenic Thiosemicarbazones 
41 a-b 42 a-o 
% % 
Cmpd Ar R Cmpd Ar R 
yield yield 
J:t 41a CI I "" CH3 44 42h f) H 6 
CI HO ./-
41b ct CH3 26 42i y:: .. ./- OH H 13 
Br OH 
42a d' H 27 42j ~H H 24 
OCH3 
c,J:t CCc 42b H 76 42k I '" " H 9 CI ./- OH 
Yl\ i;J\ 42c CI i "" H 45 421 H 28 HO // 
CI 
OCH3 
42d ct H 38 42m ~ H 23 H3CO // OCH3 
Br OCH3 
ct j~). 42e H 22 42n I "- H 39 CI "" 
Br N02 
42f cC~ H 31 420 c0 c0 54 ~ OH 












The 1 H NMR spectrum of a representative N-substituted ferrocenyl methyl 
thiosemicarbazone 42c is shown in Fig.4.5. A doublet at ca 0= 4.5 ppm 
integratimg for the two methylene protons of ferrocenylmethyl group and a 
triplet at ca 0= 8.5 ppm integrating for one proton of the adjacent NH 
group are some of the key spectroscopic indicators. Disappearance of the 
singlet at ca 0= 2.5 ppm due to the SCH3 protons from the 
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Figure 4.5: 1H NMR spectrum of 42c in DMSO-d6 
On the other hand, the 1H NMR spectra of piperazine-based thiosemicarbazones 
exemplified by 41 a (Fig.4.6) showed disappearance of the broad peak at 
ca 0= 7.5 ppm and the singlet at ca 0= 2.5 ppm assigned to the N-H of 
the ferrocene piperazine 48 and SCH3 proton of the thiosemicarbazone 
thioester respectively. These data helped to confirm that the target 
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Figure 4.6: 1H NMR spectrum of 41a in CDCI3 
Some specific spectral features that were observed with both aldehyde 
and ketone-derived thiosemicarbazones are as follows: 
For aldehyde-derived thiosemicarbazones: five Cp protons appeared as a 
singlet at ca 0= 4.2 ppm and other four Cp protons appeared differently in 
pairs as triplets at ca 0= 4.3 ppm and 4.1 ppm, respectively (exemplified by 
compound 42c) in Figure 5, on the other hand only two protons appeared 
at ca 0= 4.2 ppm and seven protons at ca 0= 4.1 ppm, both as singlets for 
all ketone-derived thiosemicarbazones ,exemplified by compound 41a in 
Figure 4.6. 
The 13C NMR, infrared absorbance peaks and the mass spectrometry 
confirmed the synthesis of the ferrocenic thiosemicarbazones. 
The thiosemicarbazone and their ferrocenic analogues were successfully 











4.3.1 Cyclic voltammetry 
56 
Cyclic voltammetry was developed from the discovery of polarography in 
1922 by the Czech chemist, Jaroslav Heyrovsky, for which he received a 
Nobel Prize in chemistry in 1959.[6] In the 1960s and 1970s, after going 
through a number of difficulties related to the routine use of the technique, 
significant progress was made in establishing the theory, methodology, and 
instrumentation of voltammetric techniques. [6] 
There are various types of voltammetric techniques, such as polarography, 
pulse methods, preconcentration and stripping techniques, as well as cyclic 
voltammetry. The common characteristic of all voltammetric techniques is 
that they involve the application of potential (E) to an electrode and the 
monitoring of the resulting current (/) flowing through the electrochemical 
cell. 
Cyclic voltammetry is the most widely used technique for acquiring 
qualitative information about electrochemical reactions, and is a sensitive 
electrochemical method which permits the collection of excellent data at 
low concentration of electroactive substances.l7] 
Over the last twenty years, cyclic voltammetry has become a popular tool 
in different fields such as in organic chemistry, where it is used to study 
different biosynthetic pathways[8] and to study chemically generated free 
radicals.[9] It has also been widely used in inorganic chemistry to assess 
the effects of ligands on oxidation/reduction potential of the central metal 
ion in coordination and organometallic complexes and multinuclear 
clusters.l10] On the other hand, physical and biological chemists use this 
technique for many purposes, such as for studying oxidation and reduction 











transfer and reaction mechanisms, kinetics of electron transfer processes, 
and transport, speciation and thermodynamic properties of solvated 
species.l6] 
Cyclic voltammetry consists of cycling the potential of an electrode, which 
is immersed in an unstirred solution (the reason for this will be detailed 
later in this section, pp.60) of an electroactive species, and measuring the 
resulting current. The potential of the working electrode is controlled 
against a reference electrode such as saturated calomel electrode (SCE) or 
a Ag/Ag+ electrode. The controlling potential which is applied across these 
two electrodes are considered to be an excitation signal which is a linear 
potential scan with a triangular waveform as shown in Fig. 4.7 . 
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Figure 4.7 : Typical excitation signal for cyclic voltammetry - a 
triangular potential waveform with switching potentials 
at 0.8 and -0.2 V versus SCE.[11] 
The triangular potential excitation signal sweeps the potential of the 
working electrode back and forth between two designated values (switching 
potentials) at a constant scan rate. Because the potential varies linearly 
with time, the horizontal axis can be thought of as a time axis. The 
response signal to the potential excitation is the measured current (J). The 











typical electrochemical cell for CV and 
illustrated in Fig. 4.8 below. 
resulting voltammogram are 
A) 
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Figure 4.8: A) Typical electrochemical cell for cyclic voltammetry. In this work 
the reference electrode was Ag/Ag + • the auxiliary electrode was 
Pt wire and the working electrode was a Pt disc,r11) 
8) Typical cyclic voltammogram.[11) 
-02 
Modern potentiostats utilize a three-electrode configuration that includes a 
working electrode, a reference electrode and an auxiliary electrode, as 
shown in Fig. 4.8A. The potentiostat applies the desired potential between a 
working electrode and a reference electrode. The applied potential controls 
the concentration of the redox species at the electrode surface and the 
rate of the reaction.[6] The working electrode is the electrode at which the 











electrolysis at the working electrode is provided by the auxiliary electrode. 
The auxiliary electrode is usually a platinum wire that is placed directly 
into the solution. This arrangement prevents large currents from passing 
through the reference electrode that could change its potential. Before the 
experiment oxygen is removed from the solution by bubbling with nitrogen 
gas to avoid any traces of oxygen that could give rise to a redox 
reaction. 
The measurements are plotted using computer software to produce a cyclic 
voltammogram (Fig. 4.8B). The important parameters that may be obtained 
from a cyclic voltammogram are the magnitudes of the peak potentials 
(Epc, Epa) and peak currents (ipc, ipa) of the cathodic and anodic peaks, 
respectively. Epa, Epc, ipc , and ipa give qualitative information about 
electroactive compounds, ie the information about the reversibility or 
irreversibility of the electrochemical reaction and the number of electrons 
exchanged during the process.[11] 
The peak separation between potentials Epa and Epc (f...E) can be used to 
determine the number of electrons transferred in a reversible system by 
the following relationship f...E= 59/n mV (n being the number of electrons 
transferred).[12] The half-wave potential, E1I2 , for a reversible couple is 
centered between Epa and Epc and is close to the formal reduction 
potential, EO', for the electroactive species. 
An electrochemical reaction is termed reversible if the electron transfer 
process is fast compared with other processes such as diffusion and is 
irreversible if the electrochemical reaction is due to a slow electron 
transfer rate with the working electrode,[6,12] the latter being manifested by 
an increase of the potential peak separation (f...E). For a reversible couple 











It should be noted that the higher (more positive) the half-wave potential, 
E1I2 , which is the average of Epc and Epa, the easier the electroactive 
compound is reduced at the working electrode or the more difficult it is to 
oxidize. [8] 
There are three general mass-transport processes by which species may 
be brought to an electrode surface: by migration of charged ions in an 
electric field; by convection, which is due to motion of the solution or the 
electrode; and by diffusion under the influence of a concentration gradient. 
Migration is not desirable in electrochemical reactions since it depends 
directly on the transferred number of ions in solution and the electrical 
potential gradient in the vicinity of the electrode surface.[9] Thus migration 
may increase or oppose diffusion. In order to minimize the effects of 
migration, some innocuous salt (supporting electrolyte) is added into the 
solution with at least 1 DO-fold greater concentration than the electro active 
species. 
Convection results from stirring, density gradients or temperature gradients. 
Thus to ensure movement of the electroactive species by diffusion only, 
measurements in cyclic voltammetry are made on unstirred, thermally 
insulated solutions. 
Diffusion, the movement of chemical species under the influence of a 
concentration gradient, is of great importance in voltammetric techniques.[7] 
The species (ions or molecules) will move from a high concentration area 
to a low concentration area in order to minimize or eliminate concentration 
differences which were established as soon as electrolysis began. The rate 
of diffusion is proportional to the gradient of the concentration in the 











rate of diffusion rather than the rate of the reaction itself is called 
diffusion control, and that is the requirement of all voltammetric techniques. 
4.3.2 Electrochemical behaviour of N-substituted ferrocenic 
thiosemicarbazones 
Cyclic voltammograms of various ferrocene derivatives were obtained in 
acetonitrile solution and compared to the parent ferrocene. It is noted that 
a fully reversible one-electron wave will have a peak separation of 59 mV, 
theoretically.[6] A reversible redox reaction is observed when both species, 
reduction and oxidation, rapidly exchange electrons with the working 
electrode; whereas a quasi-reversible redox reaction which some authors 
do not differentiate from irreversible redox reaction, is caused by a slow 
electron exchange of the redox species with the working electrode and 
resulting a greater peak potential than reversible redox reaction. However, 
in practice it is difficult to reach that figure and our peak separations 
ranged from 70-120 mV. In addition, it is required that the anodic and 
cathodic peak currents are of similar magnitude for reversibility. 
Ferrocene itself (Fc) is known to be electrochemically stable, providing a 
reversible one-electron couple (FigA.9), the half-wave potential of which can 
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The three intermediates, 45, 46 and 48 (Scheme 4.6, pp 51) preserved the 
shape of the ferrocene voltammogram with a one-electron couple; the E1I2 
values differed (Table 4.3), while the f1E values are smaller than that of Fc 
itself, though still in the range expected for a one-electron process. 
Table 4.3: Electrochemical data for ferrocene derivatives 
22 126 78 (00) 
45 78 359 (281) 
46 80 182 (104) 
48 67 90 (12) 
a Measured vs Ag/Ag + reference electrode 
b Relative to Fc/Fc+ reference couple 
These intermediates, 45 and 46, showed one reversible redox couple (see 
example in Fig. 4.108) with E1/2 values (referenced to the Fc/Fc+ couple) of 
281 mV and 104 mV, respectively, and are more difficult to oxidize than 
ferrocene. However, the voltammogram of 47 and 48 (Fig.4.10A) showed 
different picture, with two reversible redox couples at E1I2(P1) = - 37 mV (f1E 
(P1) = 79 mV) and E1/2 (P2) = 140 mV (f1E (P2)= 56 mV) for compound 47 
(Table 4) and an irreversible oxidation peak was observed at around 
500mV for compound 48. It appears that the amine group also underwent 
redox reaction, reversible for compound 47 but irreversible for compound 48 
(might be because of the primary and secondary character of the amine 
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Table 4.4: Ferrocene amine 47 electrochemical data 
80 246 190 
47 1.31.2 
(-61) (105) (-14) (175) 
a Measured vs Ag/Ag + reference electrode. 
b Relative to Fc/Fc + reference couple. 
79 
(-47) 
56 41 218 
(-70) (-37) (140) 
ipa , anodic peak current; ipc , cathodic peak current; Epa, anodic peak potential; 
E pc , cathodic peak potential; t:"Ep, potential peak separation; E1/2, half-wave 
potential. 
P1 is the peak resulting from the ferrocenyl moiety and P2 the peak 
resulting from the secondary amine group. The amine substituent rendered 
the ferrocene moiety slightly easier to oxidize compared with parent 
ferrocene. The introduction of thiosemicarbazide thioester into ferrocene-
amine 47 to give compound 42b (E1I2 value of 21 mV relative to Fc / FC+) 











Table 5 depicts the electrochemical data of the piperazine-derived 
thiosemicarbazones. The data show that the two synthesized piperazine-
derived compounds exhibit a quasi-reversible reaction with ipal ipc greater 
than unity. The presence of two peaks (exemplified by compound 41a, Fig. 
11A) must be due to amine group (piperazine ring) which undergoes redox 
reaction in addition to the ferrocene moiety. The ferrocenyl peak is labeled 
P1 and P2 probably arises from the piperazine moiety which may have 
undergone reduction, because the corresponding compound without that 
moiety, 42b, showed only one redox couple (Fig. 11 B); but this is not yet 
experimentally proven. The E1I2 values of compounds 41a and 41b are (P1) 




















Figure 4.11: Cyclic voltammograms of A) 41 a and 8) 42b 















Table 4.5: Electrochemical data for N- substituted ferrocenic piperazine-derived 
thiosemicarbazones 
118 (00) 23 (00) 
120 299 60 231 60 68 90 231 
4 4 
(2) (18) (37) (208) (-35) (-43) (19) (160) 
127 59 320 221 68 93 
4 9 99 (4) 271 (200) 
(9) (-59) (197) (198) (-27) (22) 
a Measured vs Ag/Ag+ reference electrode 
b Relative to Fc/Fc+ reference couple 
ipa , anodic peak current; ipc , cathodic peak current; Epa, anodic peak potential; 
Epc , cathodic peak potential; tc..Ep, potential peak separation; E1!2, half-wave 
potential. 
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With the exception of five compounds (42f, 42j, 42k, 42m and 420), all the 
N-substituted ferrocenic thiosemicarbazones (Table 4.6) show reversible 










Table 4.6: Electrochemical data for N-substituted ferrocenic thiosemicarbazones 
ipalipc Epa Epc 
Cmpd 
(Cmpd vs Fc) (Cmpd vs Fc) 
22 1 117(00) 24 (00) 
42a 1.1 127 (10) 48 (24) 
42b 1.2 131 (14) 52 (28) 
42c 1.2 141 (24) 28 (4) 
42d 1.2 120 (3) 42 (18) 
42e 1.2 135(18) 32 (8) 
42f 1.5 146 (29) 29 (5) 
429 1.1 123 (6) 43 (19) 
42h 1.2 120 (3) 47 (23) 
42i 1.1 130(13) 63 (39) 
42j 1.5 126 (9) 31 (7) 
42k 2.3 154 (37) 27 (3) 
421 1.1 126 (9) 42 (18) 
42m 3.6 144 (27) 12 (-12) 
42n 1.2 131 (34) 45 (21) 
420 2.4 150 (33) 7 (-17) 
a Measured vs Ag/Ag + reference electrode 
b Relative to Fc/Fc+ reference couple 
b.Ep E 1/2
a 
(Cmpd vs Fc) (E1/2 vs Fc)b 
93 (00) 71 (00) 
79 (-14) 88 (17) 
79 (-14) 92 (21) 
113 (20) 85 (14) 
78(-15) 81 (10) 
103(10) 84 (13) 
117 (24) 86 (15) 
80 (-7) 83 (12) 
73 (-20) 84 (13) 
67 (-26) 97 (26) 
95 (2) 79 (8) 
127 (34) 90 (19) 
84 (-9) 84 (13) 
131 (38) 78 (9) 
86 (-7) 88 (17) 
143 (50) 79 (8) 
66 
ipa , anodic peak current; ipc , cathodic peak current; Epa, anodic peak potential; E pc , cathodic 
peak potential; /l"Ep, potential peak separation; E1I2 , half-wave potential. 
The two ketone-based ferrocenic thiosemicarbazone (compounds 42b and 
42d) have E1/2 values of 21 mV and 10 mV relative to Fc/Fc+, respectively. 
All the aldehyde-derived ferrocenic thiosemicarbazones have E1/2 values 











42j and 420 have the smallest values of E1I2 (8 mV); these are the easiest 
to oxidize compared to the others. 
The electrochemical behaviour of the synthesized molecules were observed 
and discussed. Most of the synthesized molecules had shown a one 
electron reversible redox reaction except the piperazine-based 
thiosemicarbazones which showed a quasi-reversible redox reaction. 
4.4 Biological results and discussion 
4.4.1. Introduction 
As already mentioned, one of the main objectives was to evaluate the 
antiplasmodial activities of the synthetic ferrocenic thiosemicarbazone metal 
chelators. Their biological properties and electrochemical behaviour 
compared to establish whether they were correlated. 
It is useful at this point to explain a number of general points about 
biological testing and to describe some terms. The ED50 and IC50 values 
used in this section to express biological activity give the same 
information. IC refers to inhibitory concentration and is usually used when 
the assay is carried out by measuring the inhibitory activity of a certain 
compound. ED refers to the effective dose and is used when the actual 
number of parasites are counted. 
Practically, the IC50 value is the drug concentration required to cause the 
measured parameter to fall to 50% of its initial value. The ED50 value is 
the dosage of the drug required to kill half the parasite population or to 
inhibit 50% of the enzyme activity. The lower the two values, the greater 
the efficacy of the drug. 
Cytotoxicity refers to the toxicity of a compound towards mammalian 











and low or no toxicity towards mammalian cells. All the biological activity 
tests were done in duplicate. 
4.4.2 Results 
4.4.2.1 In vitro testing of thiosemicarbazone thioesters against K1 and 
307 strains 
The in vitro activities of synthesized thiosemicarbazone thioesters against 
P.falciparum the chloroquine resistant (COR) K1 strain and the chloroquine 










Table 4.7: In vitro activities of synthesized thiosemicarbazone thioesters against P. falciparum on 














Artesunate 0.0003 44d H 
(0.002) Sr 
(0.0007t2 
Cycloguanil 0.213(0.846) 0.01 (0.039) 44e 0' H 
y\ , I", 0.03 4.74 97.55 (':f/~ 
44a CH3 44f H 
Br (0.099) (15.64) (321.94) .j 'CI 
10.4 21.0 61.5 '" (j'44b H 449 H 








EDso• 1-19/m I EDso • 1-19/m I 1-19/ml 
(I-IM) (I-IM) (I-IM) 
4.9 15.9 93.6 
(16.95) (55.01) (323.87) 
3.8 5.6 >300 
(13.14) (19.37) (>1038.06) 
2.98 5.4 92.94 
(14.19) (25.71 ) (440) 
7.09 20.9 99.84 
(28.93) (85.30) (407.5) 
6.0 12.7 29.4 
(24.48) (51.83) (120) 












Table 4.7 :In vitro activities of synthesized thiosemicarbazone thioesters against P.falciparum on 
strain and chloroquine sensitive (COS) 307 strain. (Continued) 






I .. Ar 
R __ 
307 (COS) K1 (COR) 307 (COS) 
Cmpd R Ar --EOso , EOso , IJg/ml EOso , EOso, IJg/m I(IJ M) IJg/ml(IJM) (IJM) IJg/ml(IJM) IJg/m I(IJ M) --
JY\ 5.70 10.7 186.03 3.71 1.61 47.77 
44h CI 1 ~ H 44n 
(23.26) (43.67) (759.30) (16.41) (7.12) (211.37) 
.- • . . 
51\ 6.9 2.3 19.41 
Q(H 
3.35 1.4 9.00 
44i Ih' CH 3 440 H CI (23.54) (7.84) (66.24) (13.84) (5.78) (37.19) 
CI OH 
17\ 5.14 0.95 293.94 2.3 1.4 120.98 H 44p d H 44j CI --" Ih' 
CI (18.42) (3.40) (1053.54) HO OH (9.50) (5.78) (499.91) 
17\ 10.7 (jA 5.63 5.31 120.98 44k CI I ~ 4.9 53.7 44q H 




3.4 4.0 51.2 ~/) 2.93 1.86 11.66 /", .. \ 
441 tlo~ H 44r 
,,( "OH H 
(15.04) (17.69) (226.54) OCH3 (11.44) (7.26) (45.54 












Table 4.7: In vitro activities of synthesized thiosemicarbazone thioesters against P.falciparum on chloroquine resistant (COR) K1 
strain and chloroquine sensitive (COS) 307 strain. (Continued) R H A ,N~SMe 
Ar N II 
S 
Cytot. in 
EDso, EDso, ~g/ml EDso, EDso, ~g/ml 
~g/ml(~M) ~g/ml(~M) (~M) ~g/ml(~M) ~g/ml(~M) (~M) 
";CO¢ 8.25 5.89 127.91 C(\ 
0.48 0.001 <0.3 
44t H 44x CH3 
OCH~ (30.55) (21.81) (473.74) I /N (2.13) (0.004) «1.04) 
~\ <0.3 I 6.87 8.94 6.41 cT cT 0.18 0.021 44u . "" H 44y «1.33) H3CO OCH 3 OCH 3 (22.9) (29.8) (21.36) (0.625) (0.072) 
6.12 7.45 91.54 CCc; 1.10 0.8 4.29 44v H 44z H (24.18) (29.44) (361.81 (3.98) (2.89) (15.54) 
N02 1.95 0.61 3.87 
44w (:J\ H 
"N02 











As indicated earlier the preparation of the selected thiosemicarbazone 
analogues was dictated by the well reported anti-malarial properties of 
th iosemica rbazones. [13.14] 
Bipyridyl ketone-derived thiosemicarbazone thioester 44y showed lower 
activity against 307 strain compared to the corresponding methyl ketone-
derived 44x, but was more active against K1 strain than compound 44x. 
Compound 44a showed greater activity against both K1 and 307 strains 
compared to the corresponding aldehyde-derived thiosemicarbazone 
thioester 44c. The result against K1 for compound 44a is particularly 
noteworthy for in significance. 
Within the aldehyde-derived thiosemicarbazone thioesters, there were 
compounds with bromine as a substituent at either the ortho, meta or 
para position on the aromatic ring. The compound with bromine at the 
para position (compound 44d) showed slightly higher to comparable activity 
against K1 strain than the meta (compound 44c) substituted compound but 
higher (almost 2-fold) activity than the ortho brominated compound 4b. The 
activity was preserved against both strains when changing the substituent 
from bromine to chlorine. However, when a hydroxyl group was substituted 
instead of halogen, the meta position (compound 44m) became more 
active against K1 than the ortho and para positions. Compared to its 
corresponding fused bicyclic aldehyde-derived thiosemicarbazone thioester 
compound 44z which showed greater activity against both K1 and 307 
strains with ED50 values of 1.1 ~g/ml (3.98 ~M) and 0.8 ~g/ml (2.89 ~M) 
respectively, compound 441 showed weaker activity. Comparing compounds 
that are similar (44h and 44d) with respect to substitution at the para 
position, the general order of activity against both K1 and 307 strains was 
H > Br > CI. 
Considering singly halogenated and singly hydroxylated compounds, 











ED50 value of 1.21 IJg/ml (5.35 IJM), whereas 44n showed the greatest 
activity against 307 strain with an ED50 value of 1.61 IJg/ml (7.12 IJM). 
Considering the mono chlorinated compounds 44f, 44g and 44h versus the 
bis chlorinated compound 44j, the latter was the most active against both 
K1 and 307 strains with ED50 values of 5.14 IJg/ml (18.42 IJM) and 0.95 
IJg/ml (3.40 IJM), respectively. Changing the hydrogen atom on the 
azomethine carbon to methyl group resulted in a loss of activity against 
both K1 and 307 strains (compound 44i). 
In the series of compounds (440, 44p and 44r) that all had a hydroxyl 
group in the ortho position with various additional substituents, either meta 
or para, compound 44p which had hydroxyl groups at both the ortho and 
para pOSitions showed the greatest activity against both K1 and 307 
strains with ED50 values of 2.3 IJg/ml (9.5 IJM) and 1.4 IJg/ml (5.78 IJM), 
respectively. 
Within the meta alkoxylated aldehyde-derived thiosemicarbazone thioester 
series (44q, 44r, 44s, 44t and 44u), compound 44r showed the greatest 
activity against both K1 and 307 strains with ED50 value of 2.93 IJg/ml 
(11.44 IJM) and 1.86 IJg/ml (7.26 IJM), respectively. Changing the position of 
the substituent from ortho to para on the aromatic ring resulted in a loss 
of activity against both strains (compound 44s and compound 44t). 
Substitution at both the ortho and para positions did not restore the 
activity (compound 44u). 
Consideration of all the thiosemicarbazone thioesters showed that 
compound 44y was the most active against both K1 and 307 strains with 
ED50 values of 0.18 IJg/ml (0.625 IJM) and 0.021 IJg/ml (0.072 IJM) 
respectively. 
Finally a number of compounds (44a-h, 44k-m, 44s and 44u-v) were found 











sensitive (307) strain. This preferential potency against a chloroquine 
resistant strain for the aforementioned compounds is noteworthy. For the 
compounds (44i-j, 44n-r, 44t, 44w-z) that were more active against 307 
strain than against K1 strain, the stronger pyridyl chelators (44x and 44y) 
displayed an even greater potency against 307 strain compared to the 
others (44i-j, 44n-r, 44t, 44w and 44z). 
4.4.2.2 In vitro testing of thiosemicarbazone thioesters against 
Trypanosoma brucei 
It is evident from the in vitro studies of thiosemicarbazone thioesters 
against T.brucei (Table 4.8) that thioester 44x was generally the most 
active compared to other compounds with an EDso value of 0.12 iJg/ml (0.53 
iJM). The presence of a pyridine moiety on the azomethine carbon 
resulted in comparable activity as seen for compound 44y with an EDso 











Table 4.8: In vitro activities of synthesized thioesters against T. brucei 
R H 
A ,NysMe Ar N 
S 
0.0006 ex\ 4.50 99.8 
Pentamidine 44f I ~ 'CI H 
(0.0017) (18.36) (407.34) 
ct 4.37 97.6 ct 6.22 29.4 44a I~ CH 3 449 H (14.42) (322.11 (25.38) (120) 
Br CI 
CC 
5.62 61.5 ~\ 7.46 186.0 





It 1.82 93.6 4.35 19.4 44c H 44i CI CH 3 

























Table 4.8: In vitro activities of synthesized thioesters against T brucei (continued). 
EDso Cytot. EDso Cytot. 
Cmpd Ar R \-191m I \-191m I Cmpd Ar R \-191m I \-191m I 
(\-1M) (\-1M) (IJM) (IJM) 
q\ 7.72 53.7 44s 
HOft 
5.51 45.6 
44k CI I // H H 
NO, (26.71) (185.8) (21.52) (178.1) 
OCH 3 
0.77 51.2 ",coft 7.48 127.9 441 cC H 44t H // OH (3.40) (226.5) OCH3 (27.70) (473.7) 
2.96 11.2 qA 12.54 6.4 
ct 
1/ 
44m H 44u HJCO QCH 3 H 
(13.09) (49.55) OCH 3 (41.8) (21.33) 
OH 
~\ 
3.25 47.8 d 5.24 91.5 44n H 44v H 





~ 2.15 90 
.~ .\ 4.89 3.9 
440 H 44w l.:J
N02 
H / OH 







HO/l ", OH H 44x [«~yO" CH3 (>123.96) (10.74) 
,~>N 
(0.53) «13.3) 
y\ 6.43 121.0 :l\ ""'r/\ 0.15 <0.3 44q 1// H 44y t,,,,N 
OCH3 
(26.79) (504.1) (0.52) «1.04) 
f'J\ 1.50 11.7 ~~1 >30 4.3 1 ' , 
44r "('OH H 44z (~.\ H 












The dichloro substituted methyl ketone-derived thiosemicarbazone thioester 
44i showed greater activity against Tbrucei than its corresponding dichloro 
substituted aldehyde-derived thiosemicarbazone thioester 44j. The former 
had an EDso value of 4.35 j..Ig/ml (14.84 j..IM). 
Within the aldehyde-derived thiosemicarbazone thioester series in which 
was substituted bromine at either the ortho, meta or para position on the 
aromatic ring (compounds 44b, 44c and 44d), the meta position substituted 
compound 44c showed the greatest activity with an EDso value of 1.82 
j..Ig/ml (6.29 j..IM). Changing substituent from bromine to either chlorine or a 
hydroxyl group, the ortho position substitution resulted in the greatest 
activity (compound 44f, FM 57 and compound 441). Between, compound 44f 
and 441 the latter showed the greater activity with an EDso of 0.77 j..Ig/ml 
(3.40 j..IM). The order of activity against Tbrucei of compounds that were 
ortho substituted on the aromatic ring was OH > CI > Br > H. 
Considering the thioesters with one substituent on the aromatic ring 
(compounds 44a-d, 44f-h, 441-n, 44q and 44v), compound 44c and 441 
showed greater activity against Tbrucei with EDso values of 1.82 j..Ig/ml 
(6.29 j..IM) and 0.77 j..Ig/ml (3.4 j..IM), respectively. Compound 441 was more 
active than compound 44c. For compounds that had more than one 
substituent (compounds 44i-k, 440-p, 44r-u, 44w, compounds 440 and 44r 
showed the greatest activity and had EDso values of 2.15 j..Ig/ml (8.88 j..IM) 
and 1.50 j..Ig/ml (5.85 j..IM). Compound 44r was more active than compound 
440. Considering all of the compounds that had one or more substituents, 
regardless of their nature, compound 441 was the most active. 
Amongst the hydroxylated aldehyde-derived thiosemicarbazone thioesters, 
compound 441 showed better activity as stated previously. Compared to its 
corresponding fused bicyclic thiosemicarbazone thioester (compound 44z), it 











A Comparison of compound 441 with other singly hydroxylated (441, 44r, 
44m, 44n and 44s) and dihydroxylated compounds (440, 44p and 44r), 
compound 441 showed the greatest activity. 
Within the meta alkoxylated aldehyde-derived thiosemicarbazone thioester 
series, compound 44r showed the greatest activity against T.brucei with an 
ED50 of 1.50 !-Ig/ml (5.85 !-1M). Changing the position of the hydroxyl group 
from ortho to para resulted in a loss of activity [compound 44s; ED50 5.51 
!-Ig/ml (21.52 !-1M)] . 
4.4.2.3 In vitro testing of the N-substituted ferrocenic thiosemicarbazones 
against falcipains-2 & 3 and chloroquine resistant W2 strain 
The results of the biological evaluation of N-substitued ferrocenic 
thiosemicarbazones are presented in Table 4.9. The piperazine-based N-
substituted thiosemicarbazone 41a and 41 b showed better inhibition of both 
falcipains 2 and 3 (FP-2 and FP-3) and the parasite chloroquine resistant 
W2 strain compared to the corresponding ferrocene methyl-based 
compounds 42b and 42d. 
Within the group of ferrocene methyl-based thiosemicarbazones, the 
aldehyde-derived compounds 42e and 42c showed better inhibition of 
falcipains (2 and 3) compared to the corresponding ketones, 42b and 42d. 
In the singly hydroxylated ferrocene methyl-based thiosemicarbazone, 
compound 42g showed better activity against the falcipains-2 and W2 
strain (IC5o values of 19.4 !-1M and 9.23 !-1M, respectively), whereas 
compound 42f showed better activity against falcipains-3 compared to 
others. Inserting another hydroxyl group at the ortho position (compound 42i 
increased activity against falcipains and the parasite W2 strain. Among 
both mono and dihydroxylated compounds, compound 42i showed better 










Table 4.9: In vitro activities of N-substituted ferrocenic thiosemicarbazones against falcipains (FP-2 and FP-3) and the chloroquine 
resistant W2 strain. 
41 a-b 42 a-o 
FP-2 FP-3 W2 FP-2 FP-3 W2 
Cmpd Ar R -- Cmpd Ar R 111111 




CH 3 14.35 18.55 9.515 42e ct H 29.05 55.72 >20 
CI Br 
~r\ '<, 41b CH3 17.34 13.85 10.15 42f a\ H 26.11 47 17.9 I '
// OH 
Br 
yA 42a ~ H 47.21 99.83 15.72 429 I: H 19.4 99.94 9.234 OH 
42b Jj\ 
CI // 
CH 3 61.71 69.69 >20 42h HO~ H 34.93 87.65 10.06 
CI 
'<, 













Table 4.9: in vitro activities of N-substituted ferrocenic thiosemicarbazones against falcipains (FP-2 and FP-3) and the parasite 
W2 strain (continued). R H 




FP-2 FP-3 W2 FP-2 FP-3 W2 
Cmpd Ar R 
-
Cmpd Ar R --
42j ~, H 12.27 7.618 >20 42m ~ H 46.01 54.01 >20 /' OH H3CO OCH3 
OCH3 OCH3 
42k CCc~ H 22.4 29.04 14.41 42n Jj' H 15.84 22.26 >20 CI /' N02 
ft' , C:r\ 421 H 20.17 70.66 13.09 420 (""(~" 36.20 31.02 0.1149 HO // ;/N 
OCH3 











Within all the N-substituted thiosemicarbazones, compound 420 showed the 
greatest activity against parasite chloroquine resistant W2 strain, with an ICso 
of 0.11 I-/M while compound 42j showed the greatest activity against both 
falcipains 2 and 3 with ICso values of 12.27 I-/M and 7.62 I-/M, respectively. 
4.4.3 Discussion 
The bipyridyl thiosemicarbazone thioester 44y showed the greatest activity on 
both K1 and 307 chloroquine strains. These types of compounds are known 
to be potential iron chelators and excellent parasiticidal agents.l1S] Their 
mechanism of action as iron chelators appears to be complex. It has been 
proposed that since they are tridentate chelating agents, compound 44y may 
be acting by inhibiting ribonucleotide reductase, an enzyme essential for 
DNA synthesis.[16,17] In addition, tridentate chelating thiosemicarbazones have 
been also proposed to act by inhibiting dihydrofolate reductase.[18,19] 
In general, thiosemicarbazones are known to act on parasites in two ways, 
either by inhibiting metal-dependent enzymes or by forming lethal complexes 
which are directly toxic to the parasite. For example, there is evidence that 
copper complexes of thiosemicarbazones produce significant oxidative stress 
by binding endogenous reducing agents such as glutathioneYO] 
The activity of 44y is consistent with that previously observed for 
thiosemicarbazones in which the pyridine moiety of 2-acetylpyridine 
thiosemicarbazone analogues resulted in enhancement of the activity of this 
series of compounds against P.falciparum.[5,14] This result suggests that 
compounds that share structural features with 2-acetylpyridine 
thiosemicarbazone should offer excellent anti-malarial activity. 
In the testing against T.brucei, compound 44x and 44y were found to be 
the most active. This class of compounds can also chelate iron and other 
endogenous metals which makes the mechanism complicated. Nevertheless 











In the series of N-substituted thiosemicarbazones, compound 420 was found 
to be the most active (IC5o value of 0.11 IJM) against the chloroquine 
resistant W2 strain compared to the rest. With the pyridine moiety in its 
structure, this compound shares some structural features with 2-acetylpyridine 
thiosemicarbazone, a well-studied tridentate metal chelator.[5] One may 
assume that these two compounds act similarly on P.fa/ciparum by a metal 
chelation mechanism. If this compound acts by parasite iron chelation, then 
the lipophilic character of the ferrocenyl moiety is very important. 
Lipophilicity is an important physical property of iron chelators since the iron 
which is chelated most likely resides within the parasitic compartment of the 
malaria-infected red blood cell (RBC). The drug has to pass through the 
RBC parasite and membranes to get to its target site and would need to 
display high selectivity for iron compared to other endogenous transition 
metals. A correlation between the degree of lipophilicity of an iron chelator 
and its anti-plasmodial activity has been demonstratedY1] 
It had been proven that the combination of an ortho hydroxyl substituent on 
the aromatic ring (e.g. 2-hydroxy-1-naphthaldehyde) of various 
thiosemicarbazides resulted in novel tridentate hybrid chelatorsY2] Since 
Compound 42j displayed these features, it may also be considered as a 
tridentate hybrid chelator. Related to the concept of a tridentate chelator, 2-
acetylpyridine thiosemicarbazone, compound 42j may also exert its anti-
malarial activity through metal chelation. However, this hypothesis has yet to 
be proven experimentally. The ferrocenyl moiety, also present in compound 
42j, may play the same role as explained above for compound 420. 
In this series of ortho hydroxyl thiosemicarbazones, substituents other than 
methoxy at the ortho position of the hydroxyl thiosemicarbazones 
(compounds 42i; 42f and 42k) did not show greater activity than compound 











within this class of compounds clearly showed the preferred substitution of a 
methoxy group for anti-falcipain activity. 
Being metal chelators, thiosemicarbazones synthesized in this Msc thesis, 
could mechanistically also act as metal-interactive cysteine protease 
inhibitors. In other words the free thiosemicarbazone ligand may not show 
inhibition of a protease. However, in the presence of endogenous metals, 
the resulting complex may then act as the inhibitor. This is because of the 
metal-binding properties (especially as a thiolate) of thiols. Given that the 
cysteine protease active site thiol exists in the thiolate form due to 
polarization by a histidine residue in close proximity, this is a likely 
mechanism. For example Sweeney et al have reported[23] on the metal-
interactive cysteine protease inhibition of metal chelating biguanides. They 
found that the metal salt (Fe+3) alone caused less inhibition (24 % inhibition) 
of falcipain at 20 /-lM and metformin, a biguanide metal chelator, alone did 
not cause any inhibition at the same concentration. However, the Fe+3-
metformin complex at 20 /-lM caused 80 % inhibition of falcipain and 
increasing the concentration at 40 /-lM, the inhibition had also increased to 
90 %. 
Most compounds showed selective toxicity towards the parasites relative to 
mammalian cells. However, compounds 44x and 44y showed major toxicity 
to mammalin cells. Toxicity may arise from unselective chelation of 
endogenous metals owing to these compounds being strong tridentate metal 
chelators. 
4.4.4 Comparison of biological activities and electrochemical behaviour 
of N-substituted ferrocenic thiosemicarbazones 
The combined data, both biological and electrochemical, are depicted in 











Table 4.10: In vitro anti-malarial activity and electrochemical data of N-substituted ferrocenic 
thiosemicarbazone compounds. 
41a 14.350 18.550 9.515 19 & 160 
41b 17.340 13.850 10.150 22 &200 
42a 47.210 99.830 15.720 17 
42b 61.710 69.690 >20.000 21 
42c 32.470 54.170 >20.000 14 
42d 287.500 95.230 >20.000 10 
42e 29.050 55.720 >20.000 13 
26.110 47.000 17.900 15 
429 19.400 99.940 9.234 12 
42h 34.930 87.650 10.060 13 
42i 14.190 42.400 9.837 26 
42j 12.270 7.618 >20.000 8 
42k 22.400 29.040 14.410 19 
421 20.170 70.660 13.090 13 
42m 46.010 54.010 >20.000 9 
42n 15.840 22.260 >20.000 17 
420 36.200 31.020 0.1149 8 
* relative to E1I2 for Fc / Fc+ couple under same conditions 
(see Experimental) 
The important point to note in considering the data presented in Table 4.10 
is that even if the control drugs are not available, the smaller the value of 
IC50 the more active the compound and the smaller the E1/2 values the 
easier the compound is to oxidize relative to the Fc/Fc+ couple. 











compound 42j was the most active, with IC50 values of 12.270 j.lM and 
7.618 j.lM, respectively. Looking at the half-wave potential (E1/2) value (which 
is an indication of the ease of oxidation or reduction of compound), the 
smaller the value the easier the compound is to oxidize relative to Fc/ Fc+ 
couple. The most active compound 42j was shown to be easily oxidizable 
with E1/2 of 8 mV. 
For piperazine-based ferrocenic thiosemicarbazones (41a and 41b) the more 
active compound ( 41a) against both the malaria enzyme FP-2 (IC5o value of 
14.35 j.lM) and the malaria parasite W2 strain (IC5o value of 9.515 j.lM) showed 
more facile oxidation, with E1/2 values of (P1) 19 mV and (P2) 160 mV 
compared to 41 b [E1/2 of (P1) 22 and (P2) 200], but was less active against 
malaria enzyme FP-3. This potential correlation between electrochemical 
behaviour and activities against FP-2 and W2 strain suggests that the more 
active against both malaria enzyme FP-2 and malaria parasite W2 strain, the 
easier this piperazine-based ferrocenic thiosemicarbazone is to oxidize. 
However, this conclusion is tentative since it is based on two examples 
only; further examples will give a more definitive conclusion. 
Of the remaining N-substituted ferrocenic thiosemicarbazones, compounds 42j 
and 420 were the most easily oxidizable compounds, with equal E1/2 values 
of 8 mV. Derivation of any overall correlation between the biological results 
and the electrochemical behaviour of the remaining N-substituted ferrocenic 
thiosemicarbazone compounds would come from an analysis of the scatter 
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Figure 4.13: Scatter plots of ICso for FP-2, FP-3 and W2 (11M) versus E1I2(mV). 
It has been shown that [24J: 
a) The more the points tend to cluster around a straight line, the 
stronger the linear relationship between the two variables (the higher 
the correlation). 











left to upper right, the relationship between the two variables is 
positive (direct). 
c) If the line around which the points tend to cluster runs from upper 
left to lower right, the relationship between the variables is negative 
(inverse). 
d) If there exists a random scatter of points, there is no relationship 
between the two variables (very low or zero correlation). 
e) Very low or zero correlation could result from a non-linear relationship 
between the variables. 
From the perceptive view on these three plots, it is clear that there is 
no correlation between the biological data of the remaining N-substituted 
ferrocenic thiosemicarbazones and their electrochemical behaviour, 
because the points are randomly scattered. It could be that a larger and 
broader series of compounds and/or organisms/parasites (e.g. T. brucei) 
would shed more light, but that is beyond the scope of the current 
investigation. 
4.4.5 CONCLUSION 
In summary, ferrocenic metal chelators have been synthesized and SAR 
studies have been conducted. Ferrocenic metal chelator compounds have 
been designed based on the chelating thiosemicarbazone moiety. These 
thiosemicarbazones are known to have activity against multiple targets in 
parasites[14] and the lipophilic character of the ferrocenyl moiety is known to 
be crucial to the effectiveness of some reported compoundsY5] 











fa/ciparum strains K1 and 307, and compound 44y was particularly effective 
against both the chloroquine resistant K1 strain and the chloroquine 
sensitive 307 strain. The activity of this compound was attributed to its 
metal chelating ability. However, this compound was toxic to mammalian 
cells at a concentration close to the one at which it was killing the 
parasites. Thus selectivity was absent. Interestingly, a number of compounds 
(44a-h, 44k-m, 445 and 44u-v) displaying greater potency against the 
chloroquine resistant K1 strain than against the chloroquine sensitive 307 
strain were identified. This preferential potency suggests that compounds 
(44a-h, 44k-m, 445 and 44u-v) are not well recognized by the chloroquine 
resistance mechanism. Coupled with the observed generally lower toxicity 
towards mammalian cells, these compounds warrant further investigation vis-
a-vis detailed Structure-Activity Relationships, combination studies with 
chloroquine in resistant strains of the malaria parasite and mechanism of 
action studies. 
Amongst the intermediates tested against T. brucei, compounds 44y and 44x 
were found to be the most active. Their activities could bee attributed to the 
metal-interactive cysteine protease (rhodesain) inhibition mechanism of action. 
Within the N-substituted ferrocenic thiosemicarbazone series, two compounds 
were found to be active (compounds 420 and 42j). Compound 420 was 
active against chloroquine resistant W2 strain and compound 42j against 
falcipains (2 & 3). Their activities were attributed in both cases to their 
tridentate metal chelating ability. An additional factor is the presence of the 
lipophilic ferrocene moiety which presumably increases the potential to cross 
the parasite membranes and thereby access the parasite targets. 
The electrochemical behaviour of the N-substituted ferrocenic 
thiosemicarbazone compounds was studied. Amongst the two piperazine-











more active against both FP-2 and malaria parasite W2 strain than 
compound 41 b; and the former compound showed more facile oxidation of 
the ferrocenyl group than the latter (recognizing that the difference in E1I2 
values here is not much larger than the uncertainty of the measurements). 
Thus it could be concluded that there is correlation between the activity 
against the malaria parasite enzyme FP-2 and malaria parasite W2 strain 
with the electrochemical behaviour of the piperazine-based ferrocenic 
thiosemicarbazones. However, this conclusion is tentative since it is based 
on two examples only. 
The overall analysis for the remaining ferrocenic thiosemicarbazones 
presented in scatter plots, showed no correlation between the biological 
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Reactions were monitored by Thin-Layer Chromatography (TLC) using coated 
silica gel plates, detection by an ultra-violet lamp. 
Proton nuclear magnetic resonance CH NMR) spectra were recorded at ambient 
temperature using the following instruments: Varian mercury (300 MHz) or Varian 
Unity Spectrometer (400 MHz) and TMS was used as an internal standard. 
The chemical shifts (0) are given in parts per million relative to TMS 
(0=0.00). Carbon-13 nuclear magnetic resonance (13C NMR) spectra were 
recorded at 75 MHz or 100 MHz with the same internal standard. Dimethyl 
Sulfoxide (DMSO) was used in the determination of all the spectra unless 
stated otherwise. 
Mass spectra were recorded by means of a low resolution mass 
spectroscopy apparatus from the Division of Pharmacology at the University 
of Cape town and high resolution mass spectroscopy from Wits University. 
Infrared spectra were measured in solution using chloroform on a satellite 
FT-IR spectrophotometer. Micro (elemental) analysis was performed using a 
fisons EA 1108 CHNS-O instrument. Melting points were determined using a 
Reicher- Jung Thermovar (temperature range 0-350 DC) on cover slips and are 
uncorrected. 
Cyclic voltametry (CV) was carried out using a BAS-100W electrochemical 
analyzer and a 
Ag/Ag+ reference 
one-compartment three-electrode system, 
electrode (0.01 M AgN03 and 0.1 M 
comprising a 
BU4NCI04 in 











as the working electrode. The supporting electrolyte was a solution of 0.1 M 
tetrabutylammonium perchlorate in dried acetonitrile. All measurements were 
carried out on concentrations of 2-3 mM of the ligands at a scan rate of 
100 mV S-1, unless otherwise stated. The potentials E were recorded without 
IR compensation. 
All potentials reported are relative to the half-wave potential (E1/2) of a 
reference ferrocenel ferrocenium couple run under the same conditions (ca. 
0.07 V). The experiments were performed under an atmosphere of nitrogen 
at room temperature. The solutions were deoxygenated by bubbling nitrogen 
through the solution for 2 min prior to the CV run. The platinum disc 
electrode was polished after every run. 
5.2 Synthesis of thiosemicarbazide thioesters 43 
A solution of KOH ( 19.8 g, 0.3 mol) in 24 ml H20 and 
iPrOH (20 ml) were stirred in an ice-bath for 20 min. 
17.1 ml (0.3 mol) of hydrazine hydrate was added to the solution, which was 
kept < 10 cC. Ice- cold CS2 (18.2 ml, 0.3 mol) was added dropwise to the 
reaction mixture and it was stirred for 120 min. during which the solution 
turned yellow. Cold CH31 (18.7 ml, 0.3 mol) was added dropwise and a white 
precipitate formed. The reaction mixture was stirred for a further 150 min. 
and the white precipitate was collected with the aid of a filter dam, washed 
with ice- cold water (100 ml), collected and dried over MgS04 ; to afford 
white crystals (18.66 g, 50 %); bH (CDCb, 400 MHz) 8.64 (1 H, br s, -NHCS-), 
4.44 (2H, br s, NH2NHCS-), 2.64 (3H, S, SCH3). 
5.3 Synthesis of the ferrocene carboxaldehyde oxime 46 
Ferrocene carboxaldehyde 45 (5.0 g, 23.35 mmol) was placed 
in a round bottomed flask with NH20H.HCI (2.11 g, 30.36 mmol) 

















deionised H20 (15 mL) was added. The mixture was refluxed for 120 min. 10 mL 
deionised H20 was then added. The mixture was neutralized with NaHC03 the 
product extracted into CH2CI2 and dried over Na2S04. The solvent was then 
removed under reduced pressure to afford a deep red crystalline solid after 
crystallization from chloroform and hexane (4.80 g, 80 %); Rf (EtOAc:Hex 1 :4) 
0.23; DH (400 MHz; CDCI3) 8.03 (1 H, s, CH=N), 7.54 (1 H, br s, OH), 4.52 (2H, s, 
2Cp-H), 4.34 (2H, s, 2Cp-H), 4.21 (5H, s, 5Cp'-H); Dc (100 MHz, CDCI3) 149.7 
(C=N), 71.7, 70.2 (2C), 69.2 (5C), 67.8 (2C). 
5.4 Synthesis of the ferrocenylmethylamine 47 
Ferrocene carboxaldehyde oxime 46(1.0 g, 3.88 mmol) was 
placed in a 50 mL round bottomed flask. Anhydrous THF 









mixture was refluxed under an atmosphere of nitrogen for 6 h. The mixture was 
allowed to cool to room temperature before diluting with EbO (10 ml) and 
adding brine (10 ml). The product was extracted into the organic phase and the 
aqueous layer was washed with 20x30 ml of Et20. The organic extracts were 
combined and dried over K2C03. The solvent was removed under reduced 
pressure and the residue purified by chromatography on Si02 
(eluent EtOAc: Hex 1:4 then 15 % CH30H:CH2CI2) affording a red oil ( 0.71 g, 
76 %); Rf (CH30H-CH2CI2 3:2) 0.2; DH. (400 MHz, CDCI3) 4.13 (9H, s, 4Cp-H & 
5Cp'-H), 3.54 (2H, s, -CH2-N-); Dc (100 MHz, CDCI3) 91.2, 68.3 (2C), 67.6 (5C), 
67.1 (2C), 41.0. 
5.5 Synthesis of ferrocenyl methane piperazine 48 
Ferrocene carboxaldehyde 45 (1.0 g, 4.67 mmol) and ~N~ 
3~5 I I 
piperazine (0.6 g, 7.0 mmol) were allowed to stir in anhydrous '1 Fe" v NH 
MeOH (10 ml) for 4 h. NaCNBH3 (0.62 g, 9.82 mmol) was 3'~ 5 
then added and the reaction mixture allowed to stir for a further 2 h. The solvent 











1 N HCI (20 ml). The mixture was washed three times with Et20 (10 ml) and the 
aqueous layer was neutralized with Na2C03 (1 N). The product was extracted 
into DCM and dried over Na2S04. Solvent removal from the filtrate and 
subsequent purification on Si02 (eluent DCM:MeOH 1:9 then 30 % 
MeOH:DCM) afforded the product as an orange powder (0.53 g, 53 %); Rf 
(DCM:MeOH 1 :9) 0.4; DH (300 MHz, CDCI3) 6.25 (1 H, br s, NH), 4.18 (2H, s, 2Cp-
H), 4.10 (7H, s, 2Cp-H & 5Cp'-H), 3.40(2H, s, -CH2-N-), 3.15 (4H, t, J 4.8, -N-[CH2-
CH2b-N-), 2.65(4H, t, J 4.8, N-[CH2-CH2b-N-). 
5.6 Synthesis of compounds thiosemicarbazone thioesters 44a - z 
Synthesis of methyI3-[1-(2-pyridyl)ethy/idene]hydrazine 
carbodithioate 44a 
A solution of methyl hydrazinecarbodithioate 43 (1.0 eq., 4.09 mmol) and 3'-
acetophenone (1.0 eq., 4.09 mmol) in 10 ml iPrOH was mechanically stirred at 
room temperature. The product starts to precipitate out. The reaction mixture was 
stirred for an additional 2 h and cooled overnight. Crystals were collected, 
washed with cold iPrOH and air-dried. Yield 3.25 mmol (0.99 g, 80 %). 
The same procedure described above was used to make 44b-z from the 
appropriate carbonyl (ketone and/or aldehyde compound). 
Methyl -3(3-bromophenyl) hydrazinecarbodithioate 44a 
Beige crystalline product; m.p.127-128°C; I "-':: N II 5~0-. /~'r('SCH3 
4 ~ 2 S 
Rf (EtOAc:Hex 1 :9) 0.20; Ymax (CHCb/cm-1) 3026 (N-H), 3 
Br 
1423 (N=C), 1210 (C=S), 756, 663 (C-H, Ar); DH (300 MHz, CDCI3) 9.95 (1H, br s, 
NH), 7.96 (1 H, s, H-2), 7.74 (1 H, d, J 8.0, H-6), 7.53 (1 H, d, J 8.0, H-4), 7.27 (1 H, t, 
J 8.0, H-5), 2.66 (3H, s, SCH3), 2.28 (3H, s, CH3); Dc (100 MHz, CDCI3) 202.2 











LR-MS m/z 303 (Mt; Found: C, 39.86; H, 3.32; N, 9.30; S, 20.6 Calcd for C1oH11 
BrN2S2 : C, 39.61; H, 3.66; N, 9.24; S, 21.95. 
Methyl 3-(2- bromobenzylidine) hydrazine carbodithioate 44b 
2-bromobenzaldehyde (1.0 eq, 2.75 mmol) was used 
H 
and the product was obtained as a yellow powder. Y~~:~,rN /N y SCH 3 
4~D' S Yield 1.95 mmol (565 mg, 71 %); m.p:174-177°C; 3 Br 
Rf (EtOAc:Hex 1:4) 0.50; Vmax.(CHCI3/cm-1) 3020 (N-H),1427 (N=C), 1213 (C=S), 
760, 670 (C-H, Ar); OH (400 MHz, DMSO-d6 ) 13.41 (1 H, br s, NH), 8.60 (1 H, s, 
CH=N), 7.92 (1 H, dd, J 2.0 & 8.0, H-6), 7.69 (1 H, dd, J 1.2 & 8.0, H-3), 7.46 (1 H, 
td, J 1.2 & 8.0, H-5), 7.38 (1 H, td, J 2.0 & 8.0, H-4), 2.52 (3H, s, SCH3); Oe (75 
MHz, DMSO-d6) 199.0 (C=S), 144.7, 133.3, 132.3,128.2,127.1 (2C), 124.1, 16.7 
(SCH 3); LR-MS m/z 289 (Mt; Found: C, 37.75; H, 2.77; N, 9.80; S, 22.54 Calcd 
for CgHgBrN2S2 : C, 37.38; H, 3.14; N, 9.69; S, 22.17. 
Methyl 3-(3-bromobenzylidine) hydrazine carbodithioate 44c 
3-bromobenzaldehyde (1.0 eq, 2.78 mmol) was used 
and the product was obtained as a white powder. 
Yield 1.97 mmol (570 mg, 71 %); m.p:178-180 °C; Rf 
(EtOAc:Hex 1:4 ) 0.45; Vmax .(CHCI3/cm-1) 3020 (N-H), 
H 
5y'-::::1 ~N/NI(SCH3 4 ~ 2 S 
3 
Br 
1426 (N=C), 1213 (C=S), 770, 666 (C-H, Ar); OH (400 MHz, DMSO-d6) 13.34 (1 H, 
br S, NH), 8.19 (1 H, S, CH=N), 7.88 (1 H, s, H-2), 7.69 (1 H, d, J 8.0, H-6), 7.51 (1 H, 
d, J 8.0, H-4), 7.40 (1 H, t, J 8.0, H-5), 2.51 (3H, s, SCH3); oe (100 MHz, DMSO-d6) 
198.9 (C=S), 144.5, 135.8, 133.1, 131.1, 129.3, 126.5, 122.2, 16.7 (SCH3); LR-MS 
m/z 289 (Mt; Found: C, 37.69; H, 2.85; N, 9.77; S, 22.60 Calcd for CgHgBrN 2S2 : 











Methyl 3-(4- bromobenzylidine) hydrazine carbodithioate 44d 
H 3-bromobenzaldehyde (1.0 eq, 2.70 mmol) was 6 
X),"'=:::::1 ~N/N~SCH3 used and the product was obtained as a white I II 4 // 2 S 
powder. Yield 1.56 mmol (450 mg, 57 %); Br 3 
m.p:197-200 °C; Rf (EtOAc:Hex 1:9) 0.26; Vmax .(CHCI3/cm-
1
) 3020 (N-H), 1427 
(N=C), 1213 (C=S), 767, 667 (C-H, Ar); DH (400 MHz, DMSO-d6 ) 13.22 (1 H, br s, 
NH), 8.20 (1 H, s, CH=N), 7.64 (4H, m, H-2, H-3, H-4 & H-6), 2.51 (3H, s, SCH3); 
Dc (75 MHz, DMSO-d6) 198.6 (C=S), 145.0, 132.6, 131.9 (2C), 129.1 (2C), 124.0, 
16.7 (SCH3); LR-MS m/z 289 (Mt; Found: C, 37.68; H, 2.99; N, 9.91; S, 23.36 
Calcd for CgHgBrN2S2: C, 37.38; H, 3.14; N, 9.69; S, 22.17. 
Methyl 3-(benzylidine) hydrazine carbodithioate 44e 
Benzaldehyde (1.0 eq, 4.71 mmol) was used and the 6 H 
5~N/NvS% 
product was obtained as a white powder. Yield 3.32 40
2 
~ 
mmol (700 mg, 71 %); m.p:156-158°C; Rf (EtOAc:Hex 3 
1:4) 0.40; Vmax.(CHCb/cm- 1) 3013 (N-H), 1473, 1430 (N=C), 1217 (C=S), 770, 667 
(C_H, Ar); DH (400 MHz, DMSO-d6 ) 13.25 (1 H, br s, NH), 8.23 (1 H, s, CH=N), 
7.70 (2H, dd, J 2.4 & 7.2, H-2 & H-6), 7.46-7.45 (3H, m, H-3, H-4, H-5), 2.51 (3H, 
s, SCH3); Dc (75 MHz, DMSO-d6) 198.4 (C=S), 146.3, 133.4, 130.7, 128.9 (2C), 
127.3 (2C), 16.7 (SCH3); LR-MS m/z 211 (M+Ht; Found: C, 51.67; H, 4.76; N, 
13.61; S, 31.05 Calcd for C9H1ON2S2: C, 51.40; H, 4.79; N, 13.32; S, 30.44. 
Methyl 3-(2- chlorobenzylidine) hydrazine carbodithioate 44f 
2-chlorobenzaldehyde (1.0 eq, 3.55 mmol) was used H 
5OC~1 0-N/N').,/SCH3 
and the product was obtained as a yellow powder. I 2 II 
4 ~ CI S 
Yield 2.29 mmol (560 mg, 63 %); m.p:168-170 °C; Rf 3 
(EtOAc:Hex 1:4) 0.60; Vmax. (CHCI3/cm-
1
) 3013 (N-H), 1423 (N=C), 1213 (C=S), 











CH=N), 7.95 (1 H, dd, J 2.0 & 7.6, H-3), 7.53 (1 H, dd, J 1.2 & 7.9, H-6), 7.48-7.40 
(2H, m, H-4 & H-5), 2.52 (3H, s, SCH3); Dc (100 MHz, DMSO-d6) 198.99 (C=S), 
142.3, 133.7, 132.0, 130.7, 130.0, 127.7, 126.8, 16.7 (SCH 3); LR-MS m/z 245 
(Mf; Found: C, 44.42; H, 3.25; N, 11.42; S, 25.68 calcd for CgHgCIN 2S2 : C, 
44.16; H, 3.71; N, 11.45; S, 26.20. 
Methyl 3-(3- chlorobenzy/idine) hydrazine carbodithioate 449 
3-chlorobenzaldehyde (1.0 eq, 3.66 mmol) was used H 
5y~1 0..N/N~SCH3 
and the product was obtained as a white powder. II 
4 ~ 2 S 
Yield 2.33 mmol (570 mg, 64 %); m.p:157-158 °C; Rf 3 
CI 
(EtOAc:Hex 1:4) O.4Q; Ymax (CHCI3/cm-
1
) 3007 (N-H), 1427 (N=C), 1220 (C=S), 
760, 663 (C-H, Ar); DH (400 MHz, DMSO-d6 ) 13.28 (1 H, br s, NH), 8.21 (1 H, s, 
CH=N), 7.74 (1 H, d, J 2.0, H-2), 7.65 (1 H, dt, J 2.0 & 7.0, H-4 or H-6), 7.5-7.4 (2H, 
m, H-5 & H-4 or H-6), 2.52 (3H, s, SCH3); Dc (75 MHz, DMSO-d6) 198.91 (C=S), 
144.5, 135.6, 133.7, 130.8, 130.3, 126.4, 126.1, 16.7 (SCH 3); LR-MS m/z 245 
(Mf; Found: C, 44.41; H, 3.47; N, 11.52; S, 26.35 Calcd for CgHgCIN 2S2: C, 
44.16; H, 3.71; N, 11.45; S, 26.20. 
Methyl 3-(4- chlorobenzy/idine) hydrazine carbodithioate 44h 
4-chlorobenzaldehyde (1.0 eq, 3.66 mmol) was H 
d d th d t bt · d h·t ~~1 ~N/N~SCH3 use an e pro uc was 0 ame as a w I e I II 
4 ~ 2 S 
powder. Yield 2.91 mmol (715 mg, 80 %); C I 3 
m.p:187-190 °C; Rf (EtOAc:Hex 1:4) 0.35;. Y max (CHCI3/cm-
1
) 3020 (N-H), 1473, 
1423 (N=C), 1213 (C=S), 767, 670 (C-H, Ar); DH (400 MHz, DMSO-d6 ) 13.28 (1 H, 
br s, NH) 8.21 (1 H, s, CH=N), 7.72 (2H, d, J 8.5, H-2 & H-6), 7.51 (2H, d, J 8.5, H-
3 & H-5), 2.51 (3H, s, SCH3); Dc (75 MHz, DMSO-d6) 198.6 (C=S), 144.9, 135.1, 











44.57; H, 3.85; N, 11.62; S, 26.58 Calcd for CgHgCIN2S2: C, 44.16; H, 3.71; N, 
11.46; S, 26.20. 
Methyl-3(3,4- dichlorophenyl) hydrazine carbodithioate 44i 
3' A'-acetophenone (1.0 eq, 4.09 mmol) was 
used and the product was obtained as white xt HN SCH 
5 ~1 ~N/ Y 3 
crystals. Yield 3.75 mmol (1.10 g, 92 %); 41 ~2 S 
CI 3 
m.p.150-152 DC; Rf (EtOAc:Hex 1:9) 0.20; Ymax C I 
(CHCb/cm- 1) 3020 (N-H), 1423 (N=C), 1213 (C=S), 753, 666 (C-H, Ar); DH (300 
MHz, CDCI3) 9.91 (1 H, br s, NH); 7.91 (1 H, d, J 2.0, H-2), 7.62 (1 H, dd, J 2.0 & 8.7, 
H-6), 7.42 (1 H, d, J 8.7, H-5), 2.62 (3H, SCH3); 2.23 (3H, s, CH3);. Dc (75 MHz, 
CDCb) 201.2 (C=S), 145.9, 136.9, 134.3, 133.0, 130.6, 128.4, 125.6, 17.8 
(SCH 3), 12.8 (CH3); LR-MS m/z 293 (Mt, Found: C, 41.37; H, 3.27; N, 9.67; S, 
22.34 calcd for ClOHlOChN2S2: C, 40.96; H, 3.44; N, 9.55; S, 21.80. 
Methyl 3-(3,4-dichlorobenzylidine) hydrazine carbodithioate 44j 
3A-dichlorobenzaldehyde (1.0 eq, 2.85 mmol) 
was used and the product was obtained as a 
white powder. Yield 2.51 mmol (700 mg, 88 %); 
m.p:195-196 DC; Rf (EtOAc:Hex 1 :9) 0.20; 
Ymax(CHCb/cm-1) 3007 (N-H), 1433 (N=C), 1217 (C=S), 767, 663; DH (400 MHz, 
DMSO-d6 ) 13.39 (1 H, br s, NH); 8.18 (1 H, s, CH=N), 7.89 (1 H, d, J 1.7, H-2), 
7.73-7.65 (2H, m, H-5 & H-6), 2.51 (3H, s, SCH3); Dc (100 MHz, DMSO-d6) 199.1 
(C=S), 143.5, 134.2, 132.9, 131.8, 131.2, 128.7, 127.0, 16.7 (SCH 3); LR-MS m/z 
279 (Mt; Found: C, 39.06; H, 2.66; N, 10.07; S, 22.88 Calcd for C9H8Ch N2S2: 











Methyl 3-(4-chloro-3-nitrobenzylidine) hydrazine carbodithioate 44k 
4-chloro-3-nitrobenzaldehyde (1.0 eq, 2.74 
H 
mmol) was used and the product was ~~N _N yS C H 3 
obtained as a yellow powder. Yield 2.42 C I ~2 S 
mmol (700 mg, 88 %); m.p:188-190 °C; Rf N0 2 
(EtOAc:Hex 1:4) 0.23; Ymax .(CHCI3/cm-
1
) 3013 (N-H), 1417 (N=C), 1217 (C=S), 
747, 663 (C-H, Ar); DH (400 MHz, DMSO-d6 ) 13.43 (1 H, br s, NH), 8.34 (1 H, d, J 
2.0, H-2), 8.26 (1 H, s, CH=N), 8.01 (1 H, dd, J 2.0 & 8.5, H-6), 7.84 (1 H, d, J 8.5, 
H-5), 2.52 (3H, s, SCH3); Dc (75 MHz, DMSO-d6) 199.4 (C=S), 147.9 , 142.8, 
134.1, 132.3, 131.5, 126.3, 123.9, 16.8 (SCH3); LR-MS m/z 290 (M+Ht; Found: 
C, 37.51; H, 2.57; N, 14.63; S, 22.26 Calcd for CgHsCIN302S2: C, 37.31; H, 2.78; 
N, 14.50; S, 22.13. 
Methyl 3-(2-hydroxybenzylidine) hydrazine carbodithioate 441 
Salicylaldehyde (1.0 eq, 4.17 mmol) was used and the 
H 
product was obtained as a yellow powder. Yield 3.51 5~N _N y SCH 3 
,lA,...,L S 
mmol (795 mg, 84 %); m.p:194-196°C; Rf (EtOAc:Hex 3 OH 
1:4 ) 0.30; Ymax (CHCI3/cm-
1
) 3013 (N-H), 1430 (N=C), 1213 (C=S), 770, 666 (C-H, 
Ar); DH (400 MHz, DMSO-d6 ) 13.28 (1 H, br s, NH), 10.18 (1 H, br s, OH), 8.51 (1 H, 
s, CH=N), 7.63 (1 H, dd, J 2.0 & 7.6, H-6), 7.28 (1 H, td, J 2.0 & 8.5, H-4), 6.88 (2H, 
m, H-3 & H-5), 2.5 (3H, s, SCH3 ); Dc (75 MHz, DMSO-d6) 197.4 (C=S), 157.2, 
145.0, 132.4, 127.7, 119.9, 119.1, 116.5, 16.9 (SCH3); LR-MS m/z 227 (M+Ht ; 
Found: C, 48.09; H,4.80; N, 12.61; S, 28.62 Calcd for CgH1QN20S2: C, 47.76; H, 
4.45; N, 12.28 ; S, 28.34. 
Methyl 3-(3-hydroxybenzylidine) hydrazine carbodithioate 44m 
3-hydroxybenzaldehyde (1.0 eq, 4.21 mmol) was used 











Yield 3.98 mmol (900 mg, 94 %); m.p:174-176°C; Rf (EtOAc:Hex 2:3) 0.40; Ymax 
.(CHCI3/cm-') 3020 (N-H), 1423 (N=C), 1210 (C=S), 760, 663 (C-H, Ar); DH (300 
MHz, DMSO-d6 ) 13.24 (1 H, br s, NH), 9.68 (1 H, br s, OH), 8.18 (1 H, s, CH=N), 
7.28 (1 H, t, J 8.0, H-5), 7.19 (1 H, t, J 2.0, H-2), 7.13 (1 H, dd, J 2.0 & 8.0, H-6), 6.9 
(1 H, dd, J 2.0& 8.0, H-4), 2.55 (3H, s, SCH3); Dc (75 MHz, DMSO-d6) 198.4 (C=S), 
157.7,146.8, 134.8, 130.3, 119.5, 118.3, 118.1, 16.9 (SCH3); LR-MS m/z 227 
(M+H)+; Found: C, 47.82; H, 4.33; N, 12.35; S, 28.24 Calcd for CgH1QN20Si C, 
47.76; H, 4.45 N, 12.38; S, 28.34. 
MethyI3-(4-hydroxybenzy/idine) hydrazine carbodithioate 44n 





used and the product was obtained as a light 
yellow powder. Yield 3.99 mmol (910 mg, 95 %); 




) 3022 (N-H),1426 (N=C), 1212 (C=S), 761, 667 (C-H, Ar);. DH (300 
MHz, DMSO-d6 ) 13.13 (1 H, br s, NH), 10.07 (1 H, br s, OH), 8.17 (1 H, s, CH=N), 
7.59 (2H, d, J 8.5 , H-2 & H-6), 6.88 (2H, d, J 8.5, H-3 & H-5), 2.53 (3H, s, SCH3); 
Dc(75 MHz, DMSO-d6) 197.3 (C=S), 160.1, 147.1, 129.6 (2C), 124.5, 116.1 (2C), 
16.7 (SCH3); LR-MS m/z 227 (M+Ht; Found: C, 47.38; H, 4.50; N, 12.36; S, 
28.10 calcd for CgH1QN 20S2 ·O.1H20: C, 47.76; H, 4.46; N, 12.38; S, 28.34. 
Methyl 3-(2,4-dihydroxybenzy/idine) hydrazine carbodithioate 440 
2,4-dihydroxybenzaldehyde (1.0 eq, 3.73 mmol) H 
d d th d t bt · d ;cc::" 1 ~N/N').,/SCH3 was use an e pro uc was 0 alne as a " II 
41 2 S 
light yellow powder. Yield 2.79 mmol (678 mg, 75 HO ~ OH 
%); m.p:208-210 DC; Rf (Hex:EtOac 2:3) 0.50; Ymax .(CHCI3/cm-
1
) 3020 (N-H), 1423 
(N=C), 1210 (C=S), 757, 667 (C-H, Ar); DH (300 MHz, DMSO-d6) 13.19 (1 H, br s, 
NH), 10.23 (1 H, br s, OH), 10.03 (1 H, br s, OH), 8.42 (1 H, s, CH=N), 7.47 (1 H, d, 











MHz, DMSO-d6) 195.8 (C=S), 161.5, 159.1, 146.4, 130.2, 110.6, 108.5, 102.6, 
16.9 (SCH3); LR-MS m/z 243 (M+Ht; Found: C, 44.73; H, 3.76; N, 11. 55; S, 
26.92 Calcd for C9H1ON202S2: C, 44.61; H, 4.16; N, 11.56; S, 26.47. 
Methyl 3-(2,3-dihydroxybenzy/idine) hydrazine carbodithioate 44p 
2,3-dihydroxybenzaldehyde (1.0 eq, 3.73 mmol) was used 
and the product was obtained as a yellow powder. Yield 
2.13 mmol (515 mg, 57 %); m.p: 203-205 DC; Rf 
(EtOAc:Hex 2:3) 0.23; Vmax .(CHCI3/cm-
1) 3014 (N-H), 
1429 (N=C), 1216 (C=S), 757, 667 (C-H, Ar); OH (300 MHz, DMSO-d6 ) 13.35 (1 H, 
br s, NH), 9.53 (2H, br s, OH), 8.54 (1 H, s, CH=N); 7.13 (1 H, dd, J 1.5 & 8.0, H-
4), 6.90 (1 H, dd, J 1.5 & 8.0, H-6), 6.74 (1 H, t, J 8.0, H-5), 2.57 (3H, s, SCH3); Oc 
(75 MHz, DMSO-d6) 197.0 (C=S), 146.0, 145.7, 145.6, 119.4, 119.3, 118.0, 117.6, 
16.7 (SCH3); LR-MS m/z 243 (M+Ht; Found: C, 44. 94; H, 3.91; N, 11.59; S, 
25.99 Clacd for CgH1QN20 2S2: C, 44.61; H, 4.16; N, 11.56; S, 26.47. 
Methyl 3-(-3-methoxybenzylidine) hydrazine carbodithioate 44q 
4-hydroxybenzaldehyde (1.0 eq, 3.78 mmol) was used 
H 
and the product was obtained as a beige powder. 5V~1 0--.N /N )(
SCH 3 
Yield 3.20 mmol (770 mg, 85 %); m.p:148-149 DC; 4 I ~ 2 S 
3 
Rf (EtOAc:Hex 2:3) 0.20; Vmax (CHCI3/cm-
1) 3013 (NH), OCH 3 
1433 (N=C), 1217 (C=S), 770, 667 (C-H, Ar); OH (400 MHz, DMSO-d6 ) 13.27 (1 H, 
br s, NH), 8.19 (1 H, s, CH=N), 7.36 (1 H, t, J 8.0, H-5), 7.28 (1 H, dd, J 1.2 & 8.0, 
H-6), 7.24 (1 H, t, J 1.2, H-2), 7.04 (1 H, dd, J 1.2 & 8.0, H-4), 3.78 (3H, s, OCH3), 
2.51 (3H, s, SCH3); Oc (75 MHz, DMSO-d6) 198.4 (C=S), 159.5, 146.1, 134.8, 
130.1,120.0,116.6,111.9,55.1,16.70 (SCH3); LR-MS m/z 241(M+Ht; Found: 
C, 50.43; H, 5.10; N, 11.75; S, 26.76 calcd for C1QH12N20S20.1 H20: C, 49.97; 










Methyl 3-(2-hydroxy-3-methoxybenzylidine) hydrazine carbodithioate 44r 
2-hydroxy-3-methoxybenzaldehyde (1.0 eq, 3.28 mmol) 
was used and the product was obtained as a beige 
powder. Yield 2.08 mmol (535 mg, 64 %); m.p:187-190 
°C; Rf (EtOAc:Hex 2:3) 0.50; Vmax (CHCI3/cm-
1) 3013 
103 
(N-H), 1427 (N=C), 1213 (C=S), 760, 670 (C-H, Ar); DH. (400 MHz, DMSO-d6 ) 
13.27 (1H, br s, NH), 9.60 (1H, br s, OH), 8.54 (1H, s, CH=N), 7.25 (1H, dd, J 1.2 
& 8.0, H-6), 7.03 (1 H, dd, J 1.2 & 8.0, H-4), 6.82 (1 H, t, J 8.0, H-5), 3.80 (3H, s, 
OCH3), 2.52 (3H, s, SCH3); Dc (100 MHz, DMSO-d6) 197.3 (C=S), 148.0, 146.9, 
144.4,119.4,119.3,118.5,113.9,55.9,16.7 (SCH3); LR-MS m/z 257 (M+Ht; 
Found: C, 46.52; H, 4.76; N, 10.92; S, 24.84 Calcd for C1OH12N202S2 ·0.1 H20: C, 
46.85; H, 4.72; N, 10.93; S, 25.02 .. 
Methyl 3-(4-hydroxy-3-methoxybenzylidine) hydrazine carbodithioate 445 
4-hydroxy-3-methoxybenzaldehyde (1.0 eq, 3.28 mmol) 
was used and the product was obtained as a light 
yellow powder. Yield 2.54 mmol (650 mg, 77 %); 
m.p:167-169 °C; RdEtOAc:Hex 2:3) 0.50; vmax(CHCI3/cm-
1) 
3013 (N-H), 1477, 1427 (N=C), 1217 (C=S), 760, 667 (C-H, Ar); DH (400 MHz, 
DMSO-d6) 13.12 (1 H, br s, NH), 9.64 (1 H, br s, OH), 8.11 (1 H, s, CH=N), 7.25 
(1 H, d, J 2.0, H-2), 7.13 (1 H, dd, J 2.0. & 8.3, H-6), 6.84 (1 H, d, J 8.3 , H-5), 3.79 
(3H, s, OCH3), 2.49 (3H, s, SCH3); Dc (100 MHz, DMSO-d6) 197.0 (C=S), 149.7, 
147.9, 146.8, 124.6, 122.2, 115.7, 109.9, 55.5, 16.6 (SCH 3); LR-MS m/z 257 
(M+Ht; Found: C, 47.21; H, 4.67; N, 11.05; S, 25.43 Calcd for C1OH12N202S2: C, 











Methyl 3-(3,4-dimethoxybenzy/idine) hydrazine carbodithioate 44t 
3,4-dimethoxybenzaldehyde (1.0 eq, 3.01 mmol) 
H 
was used and the product was obtained as a ~~1 ~N/NI(SCH3 
yellow powder. Yield 2.33 mmol (630 mg, 77 %); 41 // 2 S 
H3CO 3 
m.p:180-183°C; Rf (EtOAc:Hex 2:3) 0.50; OCH 3 
vmax .(CHCb/cm-
1
) 3020 (N-H), 1423 (N=C), 1213 (C=S), 760, 670 (C-H, Ar);. DH 
(400 MHz, DMSO-d6 ) 13.15 (1 H, br s, NH), 8.15 (1 H, s, CH=N), 7.28 (1 H, d, J 
2.0, H-2), 7.24 (1 H, dd, J 2.0 & 8.3, H-6), 7.02 (1 H, d, J 8.3, H-5), 3.79 (3H, s, 
OCH3), 3.78 (3H, s, OCH3), 2.51 (3H, s, SCH3); Dc (75 MHz, DMSO-d6) 197.4 
(C=S), 151.3, 149.1, 146.4, 126.1, 122.1, 111.7, 108.9, 55.6 55.4,16.7 (SCH3); 
LR-MS m/z 271 (M+Ht; Found: C, 49.25; H, 5.27; N, 10.39; S, 23.70 calcd for 
C11H15N302S2: C, 48.86; H, 5.2; N, 10.36; S, 23.72. 
Methyl 3-(2,3,4-trimethoxybenzy/idine) hydrazine carbodithioate 44u 
2,3,4-methoxybenzaldehyde (1.0 eq, 2.54 mmol) 
was used and the product was obtained as a 
white powder. Yield 2.09 mmol (630 mg, 82 %); 
m.p:162-164 DC; Rf (Hex:EtOAc 2:3) 0.60; Ymax 
(CHCb/cm- 1) 3013 (N-H), 1473, 1420 (N=C), 1210 (C=S), 763, 667 (C-H, Ar); DH 
(400 MHz, DMSO-d6 ) 13.12 (1 H, br s, NH), 8.42 (1 H, s, CH=N), 7.5 (1 H, d, J 8.9, 
H-6), 6.9 (1 H, d, J 8.9, H-5), 3.83 (3H, s, OCH3), 3.81 (3H, s, OCH3), 3.75 (3H, s, 
OCH3), 2.49 (3H, s, SCH3); Dc (75 MHz, DMSO-d6) 197.3 (C=S), 155.8, 155.2, 
142.5, 142.6, 120.7, 119.5, 108.9, 61.8, 60.4, 56.0, 16.6 (SCH3); LR-MS m/z 301 
(M+Ht; Found: C, 48.34; H, 5.32; N, 9.44; S, 21.06 Calcd for C12H16N202S2: C, 











Methyl 3-(4-dimethylaminobenzyJidine) hydrazine carbodithioate 44v 
4-dimethylaminobenzaldehyde (1.0 eq, 3.35 mmol) X),6 ~ ~ 80-L 
5 ~1 N/ I( ,rJ 
was used and the product was obtained as an 41 ~ 2 8 
(~ChN 3 
orange powder. Yield 3.16 mmol (800 mg, 94 %); 
m.p:179-182 °C; Rf (EtOAc:Hex 2:3) 0.50;. Ymax.(CHCI3/cm-1) 3020 (N-H),1430 
(N=C), 1213 (C=S), 753, 667 (C-H, Ar);. OH (400 MHz, DMSO-d6) 13.03 (1 H, br s, 
NH), 8.09 (1 H, s, CH=N), 7.51 (2H, d, J 8.7, H-2 & H-6), 6.73 (2H, d, J 8.7, H-3 & 
H-5), 2.96 (6H, s, (CH3)2-N-), 2.49 (3H, s, SCH3); Oe (100 MHz, DMSO-d6) 195.9 
(C=S), 151.9, 147.3, 128.8 (2C), 120.3, 111.7 (2C), 70.1 (2C), 16.6 (SCH3); LR-
MS m/z 254 (M+Ht; Found: C, 51.77; H, 6.00; N, 16.47; S, 25.12 Calcd for 
C11H1SN3S2· 0.1 H20: C, 52.14; H, 5.97; N, 16.58; S, 25.31. 
MethyI3-(2,6-dinitrobenzyJidine) hydrazine carbodithioate 44w 
2,6-dinitrobenzaldehyde (1.0 eq, 2.60 mmol) was used N0
2 
H 
and the product was obtained as a yellow powder. 5~N/NI(SCH3 
4V.,r S 
Yield 2.40 mmol (720 mg, 92 %); m.p:171-173°C; Rf 3 N02 
(EtOAc:hex 2:3) 0.5; Ymax (CHCI3/cm-
1) 3013 (N-H), 1427 (N=C), 1213 (C=S), 767, 
670 (C-H, Ar); OH. (400 MHz, DMSO-d6 ) 13.54 (1 H, br s, NH), 8.55 (1 H, s, 
CH=N), 8.37 (2H, d, J 8.1, H-3 & H-5), 7.90 (1 H, t, J 8.1, H-4), 2.47 (3H, s, SCH3); 
oe (75 MHz, DMSO-d6) 200.0 (C=S), 149.1, 139.1 (2C), 131.7, 128.7 (2C), 122.7, 
16.9 (SCH3); LR-MS m/z 301 (M+Ht; Found: C, 36.46; H, 2.57; N, 18.68; S, 
21.82 Calcd for C9H8N404S2: C, 35.99; H, 2.69; N, 18.66; S, 21.35. 
Methyl 3-[1-(2-pyridyl) ethyJidenejhydrazine carbodithioate 44x 
2-acetypyridine (1.0 eq, 16.36 mmol) was used and the 
product was obtained as Orange crystalline. The product 
was revealed by 1H NMR and 13C NMR as two isomers 











m.p.122-124 °C; Rf (CH30H) 0.60; Vmax (CHCI 3/cm-
1
) 3013 (NH), 1426 (N=C), 
1216 (C=S), 760, 670 (C-H, Ar); DH (300 MHz, CDCI3) 15.85 (1 H, br s, NH ZE), 
9.95 (1 H, br s, NH ZE), 8.74 (1 H, dd, J 1.8 & 4.8, H-6 ZE), 8.59 (1 H, dd, J 1.8 & 
4.8, H-6 ZE), 8.18 (1H, d, J 7.9, H-3 ZE), 7.89 (1H, td, J 1.8 & 7.9, H-4 ZE), 7.71 
(1 H, td, J 1.8 &7.9, H-4 ZE), 7.59 (1 H, d, J 7.9, H-3 ZE), 7.39 (1 H, m, H-5 ZE), 7.29 
(1 H, m, H-5 ZE), 2.67 (3H, S, SCH3 ZE), 2.64 (3H, S, SCH3 ZE), 2.45 (3H, S, CH3 
ZE), 2.44 (3H, S, CH3 ZE); Dc(100 MHz, CDCI3) 201.6 (C=S ZE), 201.0(C=S ZE), 
154.1, 152.4, 149.6 , 148.5, 147.8, 140.3, 137.6, 124.2, 124.2, 123.8, 120.8, 
21.9(SCH3 ZE), 17.71 (CH3 ZE), 17.1 (CH3 ZE), 11.1 (SCH3 ZE); LR-MS m/z 226 
(M+Ht; Found: C, 47.81; H, 4.89; N, 18.62; S, 27.75 Calcd for C9H11N3S2: C, 
47.97; H, 4.92; N, 18.65; S, 28.46. 
Methyl 3-(2-dipyridinyl methylene) hydrazine carbodithioate 44y 
Di-(2-pyridyl) ketone (1.0 eq, 2.71 mmol) was used 5' 
4' I ~ 6' 
3' /C- N and the product was obtained as an orange powder. 
Yield 2.32 mmol (670 mg, 86 %); m.p:152-153 °C; Rf 4 ~2 :N/~nSCH3 
(100 % CH30l-D 0.60;. Vmax.(CHCb/cm-
1
) 2993 (N-H), 5 /C- N S 
1427 (N=C), 1217 (C=S), 770, 666 (C-H, Ar); DH (300 MHz, DMSO-d6 ) 15.27 (1 H, 
br s, NH), 8.80-8.78 (1 H, m, Ar-H), 8.62-8.60 (1 H, m, Ar-H), 8.06 (1 H, d, J 8.2, Ar-
H), 7.87-7.79 (2H, m, Ar-H), 7.73 (1 H, d, J 7.9, Ar-H), 7.42- 7.34 (2H, m, Ar-H), 
2.66 (3H, s, SCH3); Dc (100 MHz, DMSO-d6) 202.1 (C=S), 155.3, 151.0, 148.2, 
147.9, 137.0, 136.9, 127.2, 124.3, 124.1, 123.7, 113.0, 17.3 (SCH3); LR-MS m/z 
289 (M+Ht; Found: C, 54.38; H, 3.85; N, 19.61; S, 21.76 Calcd for C13H12N4Si 
C, 54.14; H, 4.19; N, 19.43; S, 22.24. 
Methyl 3-[1 (2-hydroxynaphtanyl) methylene] hydrazine carbodithioate 44z 
2-hydroxy-1-naphthaldehyde (1.0 eq, 2.90 mmol) was 
used and the product was obtained as a brown 











213°C; Rf (EtOAc:Hex, 1 :9) 0.20; Ymax.(CHCI3/cm-
1) 3013 (N-H), 1430 (N=C), 1213 
(C=S), 757, 660 (C-H, Ar); DH (300 MHz, DMSO-d6) 13.36 (1 H, br s, NH), 11.06 
(1 H, br s, OH), 9.20 (1 H, s, CH=N), 8.77 (1 H, d, J 8.5, H-4), 7.95-7.88 (2H, m, Ar-
H), 7.58 (1 H, t, J 7.9, Ar-H), 7.39 (1 H, t, J 7.9, Ar-H), 7.24 (1 H, d, J 8.5, H-3), 2.60 
(3H,s, SCH3); Dc (100 MHz, DMSO-d6) 196.2 (C=S), 158.1, 147.7, 133.6, 131.2, 
128.8, 128.1, 128.1, 123.6, 123.1, 118.2, 109.3, 16.9 (SCH3); LR-MS mlz 277 
(M+Ht; Found: C, 56.13; H, 4.41; N, 10.13; S, 23.04 Calcd for C13H12N20S2 
0.1 H20: C, 56.49; H, 4.38; N, 10.14; S, 23.20. 
5.7 General procedure (GP) for the synthesis of N-substituted 
thiosemicarbazones 
Selected methyl 3-hydrazine carbodithioates (1.0 eq, 0.443 mmol) suspended in 
warm MeOH (EtOH). 1.0 eq (0.443 mmol) of the appropriate amine 47 and lor 48 
was added and the mixture was stirred under reflux condition for 24 h. The 
product precipitated from hot solution as reaction progressed. The 




The conditions employed for the preparation of this H rN~ 
6 ~ ~3 
compound were those described in GP for the 51 ,-,:::' "'N,NyN 3 . .05 
synthesis of thiosemicarbazones. 0.32 mmol CI 4 ; 2 S 4 of 
CI 
the methyl 3-hydrazine carbodithioate 44i and ferrocenyl methyl piperazine 48 
were used. 0.12 mmol (63 mg, 44 %) of a beige powder were obtained; m.p: 
162-164°C; Rf (EtOAc:DCM 4:1) 0.30; Ymax(CHCI3/cm-1) 3421,3020 (N-H), 1653, 











H-2), 7.72 (1H, dd, J 2.0 & 8.4, H-6), 7.65 (1H, d, J 8.4, H-5), 4.16 (2H, s, Cp-H), 
4.12 (5H, s, Cp'-H), 4.10 (2H, s, 2Cp-H), 3.79 (4H, t, J 4.8, N-(CH2-CH2h-N), 3.36 
(2H, s, N-CH2-Cp), 2.38 (4H, t, J 4.8, N-(CH2-CH2h-N), 2.25 (3H, s, CH3); Be (75 
MHz, DMSO-d6) 184.0 (C=S), 144.1, 137.5, 133.4, 132.9, 130.5, 127.8, 125.1, 
82.9, 70.2 (2C), 68.6 (5C), 68.3 (2C), 58.0 (2C), 52.28 (2C), 51.7, 12.49 (CH3); 
HRMS (FAB) mlz 528.7 (M-Ht; Found: C, 54.97; H, 5.48; N, 10.76; S, 5.88 
Calcd for C24H26 CIzFeN4S: C, 54.44; H, 4.94; N, 10.57; S, 6.04; E(P1) 112= 19mV, 
E(P2) 112= 160mV. 
Compound 41 b 
1-[1-(3-bromophenyl)ethylidineJpiperazine 
ferrocenylmethyl thiosemicarbazone 
5 ~1 0-N/N~N~ ~ 
I II 3"~5' 
4 .// 2 S 4" ~ 
H r~~3' 
The conditions employed for the 3 
Br 
preparation of this compound were those described in GP for the synthesis of 
thiosemicarbazones. Using 0.33 mmol of the methyl 3-hydrazine carbodithioate 
44a and ferrocenyl methyl piperazine 48, 0.09 mmol of the product was 
obtained as a beige powder (50 mg, 26 %); m.p: 58 - 61°C; 
Rf (EtOAc:Hex 2:3) 0.30; Vmax (CHCI3/cm-
1
) 3428, 3010 (N-H), 1642, 1520 (C=N), 
1433 (C=C), 1216 (C=S); BH (300 MHz, CDCb) 8.33 (1 H, br s, N-H), 7.82 (1 H, s, 
H-2), 7.55 (2H, d, J 7.8, H-6), 7.50 (1 H, d, J 7.8, H-4), 7.23 (1 H, t, J 7.8, H-5), 4.19 
(2H, s, 2Cp-H), 4.17 (7H, s, 2Cp-H & 5Cp'-H), 4.08 (4H, t, J 4.8, N-(CHrCH2)rN), 
3.45 (2H, N-CH2-Cp), 2.57 (4H, t, J 4.8, N-(CH2-CH2)2-N), 2.19 (3H, s, CH3); Be 
(75 MHz, CDCI3) 182.1 (C=S), 145.1, 139.6, 132.2, 129.9, 129.0, 124.6, 122.8, 
81.9, 70.3 (2C), 68.5 (5C), 68.3 (2C), 58.0 (2C), 52.3 (2C), 51.6, 12.6 (CH3); LR-
MS mlz 539 (Mt; Found: C, 51.29; H, 5.53; N, 9.21; S, 5.07 Calcd for C24H27 
BrFeN4S .H20: C, 51.72; H, 5.24; N, 10.05; S, 5.75; E(P1) 112= 22 mV, 












1 (1-methy/idinephen yl) ferrocenylmethyl thiosemicarbazone 
U
6 ~ ~ ~~' 2' 
5 ~ 1 N / ~ '--------' 3' 
The conditions employed for the 4 1 ~ 2 ~ 3"~5" 
preparation of this compound were those 3 4' 
described in GP for the synthesis of thiosemicarbazones. Using 0.95 mmol of 
methyl 3-hydrazine carbodithioate 44f and ferrocene methanamine 47, 0.26 mmol 
of the product were obtained as a red powder (97 mg, 27 %); m.p: 143-146 
°C; Rf (EtOAc:Hex 1 :4) 0.50; Vmax (KBr/cm-
1) 3314, 3075 (N-H), 1650, 1547 
(C=N), 1483, 1444 (C=C), 1284 (C=S); DH (300 MHz, OMSO-d6) 8.52 (1 H, t, J 
6.0, S=C-NH), 8.11 (1 H, s, CH =N), 7.76 (2H, dd, J 2.0 & 8.4, H-2 & H-6), 7.41-
7.37 (3H, m, H-3, H-4 & H-5), 4.51 (2H, d, J 6.0, N-CH2-Cp),. 4.33 (2H, t, J 2.0, 
2Cp-H), 4.21 (5H, s, 5Cp'-H), 4.11 (2H, t, J 2.0, 2Cp-H); Dc (75 MHz, OMSO-d6) 
176.6(C=S), 142.2, 134.2, 129.8, 128.6, 127.0, 85.7, 68.2 (2C), 68.2 (5C), 67.2 
(2C), 42.1 (CH3); LR-MS m/z 377 (Mt; Found: C, 59.82; H, 4.77; N, 11.00; S, 
8.54 Calcd for C19H19FeN3 S: C, 60.53; H, 5.07; N,11.14; S,8.50; 
E 112= 17mV. 
Compound 42b 
1-[1-(3,4-dichlorophenyl)ethy/idine] ferrocenylmethyl thiosemicarbazone 
H H~2' The conditions employed for the preparation of this 5 ~ 1 ~N/NvN ~ 3' 
1 II~" 
compound were those described in GP for the // 2 S 3" 6 5" 
CI 4 ~
synthesis of thiosemicarbazones. Using 0.34 mmol C~ 4" 
methyl 3- hydrazine carbodithioate 44i and ferrocene methanamine 47, 0.26 
mmol of the product were obtained as a beige powder (122 mg, 76 %); 
m.p:172-175°C; Rf (EtOAc:Hex 1:4) 0.40; Vmax (CHCI3/cm-
1) 3443,3020 (N-H), 
1646,1527 (C=N), 1424 (C=C), 1216 (C=S); DH(400 MHz, COCI3) 8.64 (1H, br s, 
N-NH), 7.79 (2H, br s, S=C-NH & H-2), 7.51 (1 H, d, J 8.0, H-6), 7.45 (1 H, d, J 8.0, 
H-5), 4.55 (2H, S, N-CH2-Cp), 4.33 (2H, s, 2Cp-H), 4.24 (7H, s, 2Cp-H & 5Cp'-H), 
2.27 (3H, s, CH3); Dc(100 MHz, COCh) 177.1 (C=S), 144.5, 137.4,133.9,133.1, 











m/z 459 (M- Ht; Found: C, 52.01; H, 4.05; N, 9.17; S, 6.63 Calcd for C2oH19 
CI2FeN3S: C, 52.19; H, 4.16; N, 9.13; S, 6.96; 
E 1/2= 21mV. 
Compound 42c 
1-[1-(3,4--dichlorophenyl)methylidine]ferrocenylmethyl thiosemicarbazone 
6 H H~' 2" 
rr
~1 ~N/NyN C) 3' 
The conditions employed for the preparation of I 2 ~ 2" Ef1" 
CI 4 // 3"~5" 
this compound were those described in GP for C~ 4" 
the synthesis of thiosemicarbazones. Using 0.72 mmol of methyl 3-hydrazine 
carbodithioate 44j and ferrocene methanamine 47, 0.32 mmol of the product 
were obtained as a beige powder (140 mg, 44 %); m.p: 178-180 DC; Rf 
(EtOAc:Hex 1 :4) 0.20; Ymax (KBr/cm-1) 3370 (N-H), 1650, 1531 (C=N), 1446 (C=C), 
1233 (C=S); OH (300 MHz, DMSO-d6) 11.64 (1 H, br s, N-NH), 8.74 (1 H, t, J 6.0, 
S=C-NH), 8.14 (1 H, d, J 2.0, H-2), 8.03 (1 H, s, CH =N), 7.74 (1 H, dd, J 2.0 & 8.4, 
H-6), 7.67 (1 H, d, J 8.4, H-5), 4.52 (2H, d, J 6.0, N-CH2-Cp). 4.33 (2H, t, J 2.0, 
2Cp-H), 4.20 (5H, s, 5Cp'-H), 4.10 (2H, t, J 2.0, 2Cp-H); Oe (75 MHz, DMSO-d6 ) 
176.7 (C=S), 139.4, 135.0, 131.8, 131.7, 130.8, 128.1, 127.4, 85.7,68.5 (2C), 
68.2 (5C), 67.2 (2C), 42.1 (CH3); LR-MS m/z 444.9 (M +Ht; Found: C, 50.9; H, 
3.76; N, 9.13; S, 6.97 Calcd for C19H17 Ch FeN 3S: C, 51.41; H, 3.85; N, 9.46; S, 
7.22; E 112= 14 mY. 
Compound 42d 
1-[1-(3-bromophenyl)ethylidine]ferrocenyl methyl thiosemicarbazone 
The conditions employed for the preparation Of¢t H H ~2' 
1 ~ /N N ~ 
this compound were those described in GP 5 I ~ N Y Ef1" 3' 
for the synthesis of thiosemicarbazones. 4 12 S 3"Q,5" 
4" 
Using 0.33 mmol of methyl3-hydrazine Br 
carbodithioate 44a and ferrocene methanamine 47, 0.12 mmol of the product 











m.p:117-119 °C; Rf (EtOAc:Hex 1:4) 0.30; Vmax (CHCI3/cm-
1
) 3431, 3020 (N-H), 
1650, 1524 (C=N), 1465 (C=C), 1218 (C=S); DH (400 MHz, CDCI3) 8.72 (1 H, br s, 
N-NH), 7.86 (2H, br s, S=C-NH & H-2), 7.63 (1 H, d, J 7.8, H-6), 7.54 (1 H, d, J 7.8, 
H-4), 7.23 (1 H, t, J 7.8 ,H-5), 4.53 (2H, s, N-CH2-Cp), 4.32 (2H, s, 2Cp-H), 4.20 
(7H, s, 2Cp-H & 5Cp'-H), 2.28 (3H, s, CH3); Dc (100 MHz, CDCb) 177.2 (C=S), 
145.5, 139.6, 132.6, 130.1, 129.3, 124.9, 122.9, 84.3, 68.6 (2C), 68.2 (5C), 67.7 
(2C), 43.8, 13.9(CH3); LR-MS m/z 471 (M+ Ht; Found: C, 51.07; H, 3.92; N, 
8.54; S, 6.31 Calcd for C2oH20 BrFeN3 S: C, 51.08; H, 4.28; N, 8.93; S, 6.82; 
E 112= 10 mY. 
Compound 42e 
1-[1-(3-bromophenyJ)methyJidine] ferrocenyJmethyJ thiosemicarbazone 
6 H H~. 2' 
I II 7 ~. The conditions employed for the preparation of this 591:' ~N/NVN c=:: 3 
compound were those described in GP for the 4 ~ 2 S 3·~5· 
synthesis of thiosemicarbazones. Using 0.69 mmol Br 
4" 
of methyl 3-hydrazine carbodithioate 44c and ferrocene methanamine 47, 0.15 
mmol of the product were obtained as a dark-brown powder (68mg, 22%); 
m.p:168-171 °C; Rf (EtOAc:Hex 1:4) 0.50; Vmax (KBr/cm-
1
) 3370 ( N-H), 1655, 
1531 (C=N), 1446 (C=C), 1233 (C=S); DH (300 MHz, DMSO-d6) 11.57 (1 H, br s, N-
NH), 8.65 (1 H, t, J 6.0, S=C-NH), 8.07 ( 1 H, t, J 2.0, H-2), 8.05 (1 H, s, CH=N), 7.71 
(1 H, dd, J 2.0 & 7.5, H-6 ), 7.58 (1 H, dd, J 2.0 & 7.5, H-4), 7.36 (1 H, t, J 7.5, H-5), 
4.52 (2H, d, J 6.0, N-CH2-Cp), 4.33 (2H, t, J 2.0, 2Cp-H), 4.21 (5H, s, 5Cp'-H), 4.11 
(2H, t, J 2.0, 2Cp-H); Dc (100 MHz, DMSO-d6) 176.7 (C=S), 140.5, 136.6, 132.3, 
130.7,128.8,126.7,122.2,85.7,68.4 (2C), 68.2 (5C), 67.3 (2C), 41.1 (CH3); LR-
MS m/z 456 (Mt; Found: C, 49.88; H, 3.72; N, 9.05; S, 7.11 Calcd for C19H18 












1-[1-(2-hydroxyphenyJ)methy/idine] ferrocenyJmethyJ thiosemicarbazone 
The conditions employed for the preparation of 6 H H ~2' 
~ _N N c=:> 
this compound were those described in GP 5lAr>L N Y 2" ?;" 3' 
for the synthesis of thiosemicarbazones. 4 -: 2 OH S 3'''~5'' 
4" 
Using 0.88 mmol of methyl 3-hydrazine carbodithioate 441 and ferrocene 
methanamine 47, 0.27 mmol of the product were obtained as a brown 
powder (107 mg, 31 %); m.p:59-62 °C; Rf (EtOAc:Hex 1 :4) 0.30; Vmax (KBr/cm-1) 
3370- 3118 (OHIN-H), 1650, 1531 (C=N), 1446 (C=C), 1233 (C=S); DH (300 MHz, 
DMSO-d6) 11.44 (1 H, br s, N-NH), 9.91 (1 H, br s, OH), 8.42 (1 H, s, CH =N), 8.40 
(1 H, t, J 6.0, S=C-NH), 7.87 (1 H, dd, J 2.0 & 7.8, H-6), 7.24 (1 H, td, J 2.0 & 7,6, 
H-4), 6.86- 6.79 (2H, m, H-3 & H-5), 4.49 (2H, d, J 6.0, N-CH2-Cp). 4.32 (2H, t, J 
2.0, 2Cp-H), 4.20 (5H, s, 5Cp'-H), 4.11 (2H, t, J 2.0, 2Cp-H); Dc (100 MHz, DMSO-
d6) 176.2 (C=S), 156.4, 144.8, 139.5, 131.1, 126.3, 119.2, 116.1,85.8,68.2 (2C), 
67.9 (5C), 67.30 (2C), 42.09 (CH3); LR-MS m/z 393 (M+Ht; Found: C, 55.32; H, 
4.66; N, 9.81; S, 7.40 Calcd for C19H19 FeN30S .H20: C, 55.66; H, 5.16; N, 
10.25; S, 7.82; E 1/2= 15 mY. 
Compound 429 
1-[1-(3-hydroxyphenyJ)methy/idine] ferrocenyJmethyJ thiosemicarbazone 
The conditions employed for the preparation of H H ~' 
6 ~ N N 2 
this compound were those described in GP 5~N- I( 2~" 3' 
for the synthesis of thiosemicarbazones. ;y, 2 S 3"95" 
Using 0.88 mmol of methyl 3-hydrazine OH 
carbodithioate 44m and ferrocene methanamine 47, 0.46 mmol of the product 
were obtained as a yellow powder (182 mg, 52 %); m.p:166-169 °C; Rf 
(EtOAc:Hex 2:3) 0.50; Vmax (KBr/cm-1) 3370-3118 (OH/N-H), 1650, 1531 (C=N), 
1446 (C=C), 1233 (C=S ); DH (300 MHz, DMSO-d6) 11.44 (1 H, br s, N-NH), 9.53 











7.5, H-5), 7.15 (1 H, d, J 7.5, H-4), 7.12 (1 H, t, J 2.0, H-2), 6.80 (1 H, dd, J 2.0 & 
7.5, H-6), 4.48 (2H, d, J 6.0, N-CH2-Cp). 4.31 (2H, t, J 2.0, 2Cp-H), 4.19 (5H, s, 
5Cp'-H), 4.10 (2H, t, J 2.0, 2Cp-H); Dc (100 MHz, DMSO-d6) 176.5 (C=S), 157.6, 
142.6, 135.3, 129.6, 118.2, 117.1, 113.5, 85.7, 68.23 (2C), 68.13 (5C), 67.32 (2C), 
42.13 (CH 3); LR-MS mlz 393 (M+Ht; Found: C, 55.94; H, 4.47; N, 10.26; S, 7.72 
Calcd for C19H19 FeN 30S. 0.75 H20: C, 56.27; H, 5.09; N, 10.36; S, 7.90; E 1/2= 
12 mV. 
Compound 42h 
1-[1-(4-hydroxyphenyJ)methy/idine] ferrocenyJmethyJ thiosemicarbazone 
xr
6 ~ ~ ~~' 2' 
5 ~1 N/ I( ~ 3' 
The dT I d for the I 2 S 2 e'\' con I Ions emp oye HO 4 -; 3"~5" 
preparation of this compound were 4" 
those described in GP for the synthesis of thiosemicarbazones. Using 0.88 
mmol of methyl 3-hydrazine carbodithioate 44n and ferrocene methanamine 47, 
0.05 mmol of the product were obtained as a brown powder (20 mg, 6 %); 
m.p: 186-189 °C; Rf (EtOAc:Hex 2:3) 0.30; Vmax (KBr/cm-1) 3370- 3118 (OH/N-H), 
1650,1531 (C=N), 1446 (C=C), 1233 (C=S); DH(300 MHz, DMSO-d6) 11,20 (1H, 
br s, N-NH), 9.77 (1 H, br s, OH), 8.36 (1 H, t, J 6.0, S=C-NH), 8.01 (1 H, s, CH =N), 
7.61 (2H, d, J 8.7, H-2 & H-6), 6.80 (2H, d, J 8.7, H-3 & H-5), 4.49 (2H, d, J 6.0, N-
CH2-Cp14.32 (2H, t, J 2.0, 2Cp-H), 4.21 (5H, s, 5Cp'-H), 4.12 (2H, t, J 2.0, 2Cp-H); 
. Dc (100 MHz, DMSO-d6) 176.2 (C=S), 159.3, 142.8, 128.8 (2C), 125.0, 115.6 (2C), 
85.9, 68.2 (2C), 68.1 (5C), 67.3 (2C), 42.0 (CH 3); LR-MS mlz 393 (M+Ht; 
Found: C, 57.55; H, 5.18; N, 10.44; S, 8.86 Calcd for C19H19 FeN 30S: C, 58.02; 
H, 4.86; N, 10.68; S, 8.15; 













The conditions employed for the preparation GC6~ 0- ~ ~ ' 2' 
5 ~1 N~ l( ~ 3' 
of this compound were those described in I ~ 2 S $ 
4 0 H 3" '-----/ 5" 
GP for the synthesis of thiosemicarbazones. 03
H 
4" 
Using 0.83 mmol of the methyl 3-hydrazine carbodithioate 44p and ferrocene 
methanamine 47, 0.11 mmol of the product were obtained as an orange 
powder (45 mg, 13 %); m.p: 195-197 °C; Rf (EtOAc:Hex 2:3) 0.20; Vmax 
(KBr/cm-1) 3370 - 3118 (OH/N-H), 1650, 1531 (C=N), 1446 (C=C), 1233 (C=S); 
DH (400 MHz, DMSO-d6 ) 11.43 (1 H, br s, N-NH), 9.47 (1 H, br s, OH), 8.91 (1 H, br 
s, OH), 8.40 (1 H, s, CH =N), 8.35 (1 H, t, J 6.0, S=C-NH), 7.30 (1 H, dd, J 2.0 & 8.0, 
H-6), 6.78 (1 H, dd, J 2.0 & 8.0, H-4), 6.62 (1 H, t, J 8.0, H-5), 4.46.(2H, d, J 6.0, N-
CH2-Cp), 4.29 (2H, t, J 2.0, 2Cp-H), 4.18 (5H, s, 5Cp'-H), 4.09 (2H, t, J 2.0, 2Cp-
H); Dc (100 MHz, DMSO-d6 ) 176.3 (C=S), 145.6, 145.3, 140.2, 120.9, 118.9, 
116.6, 116.4, 85.8, 68.2 (2C), 68.1 (5C), 67.3 (2C), 42.1; LR-MS m/z 409 (Mt; 
Found: C, 56.11 ; H, 4.32; N, 10.68; S, 8.00 Calcd for C19H19 FeN 30 2S: C, 55.75; 





6 ~ ~ ~~' 2' 
5 ": 1 N~ Y ~ 3' 
The conditions employed for the preparation of 41 // 2 S 3" 5 5" 
this compound were those described in GP for 3 OH Y 
OCH3 
the synthesis of thiosemicarbazones. Using 0.78 mmol of methyl-
3-hydrazine carbodithioate 44r and ferrocene methanamine 47, 0.19 mmol of 
the product were obtained as a yellow powder (80 mg, 24 %); m.p: 214-215 
°C; Rf (EtOAc:Hex 2:3) 0.40; Vmax (KBr/cm-
1
) 3370-3118 (OHIN-H), 1645, 1531 
(C=N), 1446 (C=C), 1233 (C=S); DH (400 MHz, DMSO-d6 ) 11.46 (1 H, br s, N-NH), 











J 7.9, H-6), 6.95 (1 H, d, J 7.9, H-4), 6.75 (1 H, t, J 7.9, H-~), 4.49.(2H, d, J 6.0, N-
CH2-Cp), 4.29 (2H, t, J 2.0, Cp-H), 4.18 (5H, s, Cp'-H), 4.09 (2H, t, J 2.0, Cp-H), 
3.78 (3H, s, OCH3); Oc (100 MHz, DMSO-d6) 176.4 (C=S), 148.0, 146.0, 139.4, 
120.7,119.0,117.7,112.9,85.8,68.2 (2C), 68.1 (5C), 67.3 (2C), 55.9,42.1 (CH 3); 
HRMS (FAB) m/z 424 (M+Ht; Found: C, 56.39; H, 4.99; N, 9.96; S, 7.54 Calcd 
for C2oH21 FeN30 2S: C, 56.75; H, 5.00; N, 9.92; S, 7.57; 
E 1/2= 8 mV. 
Compound 42k 
1-[1-(2-hydroxy-1-naphtyl)methy/idine] ferrocenylmethyl thiosemicarbazone 
7 
6 ~ 8 
The conditions employed for the preparation 1 8' ~ ~ ~~. 2' 
5 ~ 1 N~ Y '-----' 3' 
of this compound were those described in GP 4'1 2 ~ 2" €t;" 
4 ~ OH 3,,95" 
for the synthesis of thiosemicarbazones. Using 3 4" 
0.72 mmol of methyl 3-hydrazine carbodithioate 44z and ferrocene 
methanamine 47, 0.06 mmol of the product were obtained as a green powder 
(28mg, 8%); m.p:110-112 DC; Rf (EtOAc:Hex 2:3) 0.40; Ymax (KBr/cm-1) 3370-
3118 (OH/N-H), 1645, 1531 (C=N), 1446 (C=C), 1233 (C=S); OH (400 MHz, 
DMSO-d6), 9.11 (1 H, s, CH =N), 8.06 (1 H, d, J 8.4, H-4), 7.72 (1 H, d, J 9.3, H-5), 
7.63 (1H, d, J 9.3, H-8), 7.41 (1H, t, J 9.3, H-7), 7.18 (1H, t, J 9.3, H-6), 6.77 (1H, 
d, J 8.4, H-3), 4.49 (2H, d, J 6.0, N-CH2-Cp), 4.32 (2H, t, J 2.0, 2Cp-H), 4.21 (5H, 
s, 5Cp'-H), 4.12 (2H, t, J 2.0, 2Cp-H); Oc (100 MHz, DMSO-d6) 178.6 (C=S), 159.0, 
137.9,135.1,129.6,128.6,126.4,125.9 (2C), 122.8, 119.1, 106.3,85.9,69.3 (2C), 
68.7 (5C), 68.0 (2C), 50.4; HRMS (FAB) m/z 443 (M+Ht; Found: C, 60.45; H, 
4.71; N, 9.02; S, 6.98 Calcd for C23H21 FeN30S .H20: C, 60.1; H, 5.03; N, 9.13; 











1-[1-( 4-h ydroxy-3-methoxyphen yl)meth ylidine] ferrocen ylmeth yl 
thiosemicarbazone 
116 
6 H H~ 
r;r
~1 ~N/NI(N ~3' 
The conditions employed for the preparation I // 2 S ~ 
H 0 4 3" '------' 5" 
of this compound were those described in 03
CH3 
4" 
GP for the synthesis of thiosemicarbazones. Using 0.78 mmol of methyl 3-
hydrazine carbodithioate 445 and ferrocene methanamine 47, 0.22 mmol of 
the product were obtained as a brown powder (95 mg, 28 %); mp:188- 191 
°C; Rf (EtOAc:Hex 2:3) 0.45; Vmax (KBr/cm-
1) 3370-3118 (OH/N-H), 1645, 1531 
(C=N), 1446 (C=C), 1233 (C=S); DH (400 MHz, DMSO-d6) 11.36 (1 H, br s, N-NH), 
9.37 (1 H, br s, OH), 8.35 (1 H, t, J 6.0, S=C-NH), 8.00 (1 H, s, CH=N), 7.38 (1 H, d, J 
2.0, H-2 ), 7.09 (1 H, dd, J 2.0 & 8.0, H-6), 6.79 (1 H, d, J 8.0, H-5), 4.47 (2H, d, J 
6.0, N-CH2-Cp), 4.28 (2H, t, J 2.0, 2Cp-H), 4.21 (5H, s, 5Cp'-H), 4.10 (2H, t, J 2.0, 
2Cp-H), 3.75 (3H, s, OCH3); Dc (100 MHz, DMSO-d6) 176.2 (C=S), 148.9, 148.0, 
143.0,125.4,122.0,115.4,109.6,86.1,68.2 (2C), 67.9 (5C), 67.3 (2C), 55.7,41.9 
(CH 3); HRMS (FAB) m/z 423 (Mt; Found: C, 56.16; H, 4.86; N, 9.74; S, 7.33 





6 '" /~ ~~ 
5 ,-,::1 N 'IT ~3' 
The conditions employed for the preparation of I ~ 2 S ~ 
~ 4 3 ~ 3"~5" 
this compound were those described in GP for ~ 4" 
the synthesis of thiosemicarbazones. using 0.67 mmol of methyl 3-hydrazine 
carbodithioate 44u and ferrocene methanamine 47, 0.15 mmol of the product 
were obtained as an orange powder (72mg, 23%); m.p:61-63 °C; Rf 
(EtOAc:Hex 1:4) 0.20; Vmax (KBr/cm-1) 3370 (N-H), 1645, 1531 (C=N), 1446 
(C=C), 1233 (C=S); DH (300 MHz, DMSO-d6) 11.4 (1 H, br s, N-NH), 8.38 (1 H, t, J 











5), 4.46 (2H, d, J 6.0, N-CH2-Cp). 4.29 (2H, t, J 2.0, 2Cp-H), 4.19 (5H, s, 5Cp'-H), 
4.09 (2H, t, J 2.0, 2Cp-H), 3.80 (3H, s, OCH3), 3.78 (3H, s, OCH3), 3.73 (3H, s, 
OCH3);. Dc (100 MHz, DMSO-d6) 176.3 (C=S), 155.0, 152.7, 141.6, 138.4, 120.6, 
120.2, 108.6, 85.9, 68.2 (2C), 68.1 (5C), 67.3 (2C), 61.8, 60.4, 56.0, 42.0 (CH3); 
HRMS (FAB) m/z 467; Found: C, 56.57; H, 5.35; N, 9.10; S, 7.10 Calcd for 
C22H25 FeN30 3S. H20: C, 54.48; H, 5.19; N, 8.65; S, 6.59, E 1/2= 9mV. 
Compound 42n 
1[1-(4-chloro-3-nitrophenyl)methy/idine]ferrocenylmethyl thiosemicarbazone 
r;r~1 ~N~~~~~3' The conditions employed for the I II preparation of this compound were CI 4 '1 2 S 395 ' 
those described in GP for the synthesis of N02 
thiosemicarbazones. Using 0.69 mmol of methyl 3-hydrazine carbodithioate 44k 
and ferrocene methanamine 47, 0.27 mmol of the product were obtained as a 
beige powder (121 mg, 39 %); m.p:182-185°C; Rf (EtOAc:Hex 2:3) 0.40; Ymax 
(KBr/cm-1) 3370 (N-H), 1650, 1531 (C=N), 1446 (C=C), 1233 (C=S); DH (300 
MHz, DMSO-d6) 11.72 (1 H, br s, N-NH), 8.80 (1 H, t, J 6.0, S=C-NH), 8.48 (1 H, d, J 
2.0, H-2), 8.10 (1H, s, CH=N), 8.09 (1H, dd, J 2.0 & 8.4, H-6), 7.81 (1H, d, J 8.4, 
H-5), 4.53 (2H, d, J 6.0, N-CH2-Cp), 4.33 (2H, t, J 2.0, 2Cp-H), 4.19 (5H, s, 5Cp'-
H), 4.09 (2H, t, J 2.0, 2Cp-H); Dc (75 MHz, DMSO-d6) 176.8 (C=S), 148.1, 138.4, 
134.9,131.7,131.6,124.8,122.8, 85.5,68.4 (2C), 68.2 (5C), 67.2 (2C), 42.1 
(CH3); LR-MS m/z 456 (M+Hf; Found: C, 49.99; H, 3.46; N, 11.94; S, 7.64 
Calcd for C19H17 CI FeN3 SO: C, 50.15; H, 3.76; N, 12.26; S,7.02; E 1/2= 17mV. 
Compound 420 
1(2-bipyridinyl) ferrocenylmethyl thiosemicarbazone 
The conditions employed for the preparation of 
compound were those described in GP for the synthesis 
5'" 
4' "'" 6'" 
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~
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'"",2 "N' N N " 
I n 2" et;, 












of thiosemicarbazones. Using 0.69 mmol of methyl 3-hydrazine carbodithioate 
44y and ferrocene methanamine 47, 0.37 mmol of the product were obtained 
as a light green powder (170 mg, 54 %); m.p:169-172 °C; Rf (100 % MeOH ) 
0.45; Vmax (KBr/cm-1) 3370 ( N-H), 1650, 1531 (C=N), 1446 (C=C), 1233 (C=S); OH 
(300 MHz, DMSO-d6) 13.43 (1 H, br s, N-NH), 8.85-8.82 (2H, m, S=C-NH & 
pyridine-H), 8.58-8.56 (1 H, m, pyridine-H), 8.16 (1 H, dt, J 0.9 & 7.8, pyridine-H), 
8.01-7.90 (2H, m, pyridine-H), 7.60-7.55 (1 H, m, pyridine-H), 7.47-7.43 (2H, m, 
pyridine-H), 4.53 (2H, d, J 6.0, N-CH2-Cp). 4.32 (2H, t, J 2.0, 2Cp-H), 4.17 (5H, s, 
5Cp'-H), 4.11 (2H, t, J 2.0, 2Cp-H); Oc (100 MHz, DMSO-d6) 176.9 (C=S), 155.1, 
151.1,148.6,148.4,148.1,141.3,137.5,137.0,126.9, 124.7, 123.84,85.2,68.2 
(2C), 68,1 (5C), 67.3 (2C), 42.6 (CH3); LC-MS m/z 455 (M+Ht; Found: C, 59.72; 
H, 4.42; N, 15.54; S, 7.41 Calcd for C23H21FeN5 S. 0.5 H20: C, 59.66; H, 4.78; 
N, 15.11; S, 6.91; E 112= 8mV. 
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